Stock Name | Peer Group Rank | RS Rating | 1 Month RS | 3 Month RS | Listing Date | Basic Industry | Market Cap(Cr.) | 1 Day Returns(%) | 1 Week Returns(%) | 1 Month Returns(%) | 3 Month Returns(%) | 6 Month Returns(%) | 1 Year Returns(%) | % from 52W High | % from 52W Low | Chart Type | Stock Price(₹) | 200 Days MA | 150 Days MA | 50 Days MA | 20 Days MA | 200 Days EMA | 50 Days EMA | 21 Days EMA | 20 Days EMA | 10 Days EMA | 30 Days Average Rupee Volume(Cr.) | 1 Month High | 3 Month High | Float Shares(Cr.) | Index | 52 Week High | Volume Spike | Gap Up | Dense Volume | Sector | Free Float(%) | Is HVE | HVE Date | Is Positive Volume HVE | Is HVY | HVY Date | Is Positive Volume HVY | Is HVQ | HVQ Date | Is Positive Volume HVQ | Day Range(%) | Is F&O Stock | Circuit Limit | RVOL | Daily Rupee Turnover 20(Cr.) | Daily Rupee Turnover 50(Cr.) | Daily Rupee Turnover 100(Cr.) | Is NR7 | 20 Days MA Volume | 50 Days MA Volume | 200 Days EMA Volume | 50 Days EMA Volume | 20 Days EMA Volume | Trend Reversal | % from 52W High 200 Days EMA Volume | 200 Days EMA RS | 50 Days EMA RS | 20 Days EMA RS | % from 52W High RS | 5 Days MA ADR(%) | 14 Days MA ADR(%) | 20 Days MA ADR(%) | 30 Days MA ADR(%) | % Days in 125: EMA50 today > yesterday | % Days in 125: Today's price > EMA50 | % from ATH | Quarterly Results Date | Gap Up % | MA Uptrend | FVG | Backtesting Closing Data | Highest Close Since Last Quarter | Past Result Dates | Company Name | Returns since Earnings(%) | Max Returns since Earnings(%) | Latest Investor Presentation Link | 3 Day Range(%) | 5 Day Range(%) | 7 Day Range(%) | 20 Day Range(%) | Horizontal Resistance Line Data | Tight Zone Data | Inside Bar Dates | VCP Drawings Data | Net Profit Latest Quarter | Net Profit Previous Quarter | Net Profit 2 Quarters Back | Net Profit 3 Quarters Back | Net Profit Last Year Quarter | Net Profit 5 Quarters Back | Net Profit 6 Quarters Back | Net Profit 7 Quarters Back | QoQ % Net Profit Latest | YoY % Net Profit Latest | EPS Latest Quarter | EPS Previous Quarter | EPS 2 Quarters Back | EPS 3 Quarters Back | EPS Last Year Quarter | EPS 5 Quarters Back | EPS 6 Quarters Back | EPS 7 Quarters Back | QoQ % EPS Latest | YoY % EPS Latest | EPS Last Year | EPS 2 Years Back | Sales Latest Quarter | Sales Previous Quarter | Sales 2 Quarters Back | Sales 3 Quarters Back | Sales Last Year Quarter | Sales 5 Quarters Back | Sales 6 Quarters Back | Sales 7 Quarters Back | QoQ % Sales Latest | YoY % Sales Latest | Sales Growth 5 Years(%) | OPM Latest Quarter | OPM Previous Quarter | OPM 2 Quarters Back | OPM 3 Quarters Back | OPM Last Year Quarter | OPM 5 Quarters Back | OPM 6 Quarters Back | OPM 7 Quarters Back | QoQ % OPM Latest | YoY % OPM Latest | Latest Quarter | ROE(%) | ROCE(%) | D/E | OPM TTM(%) | P/E | FII % change QoQ | DII % change QoQ | Promoter % change QoQ | PEG | Forward P/E | Historical P/E 5 Years | Company Info | Promotor Holding Latest Quarter(%) | Public Holding Latest Quarter(%) | FII Holding Latest Quarter(%) | DII Holding Latest Quarter(%) | Promotor Holding Previous Quarter(%) | FII Holding Previous Quarter(%) | DII Holding Previous Quarter(%) | Price to Book | Enterprise Value(Cr.) | Enterprise Value/EBITDA | Enterprise Value/Sales |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 | 70 | 15 | 83 | 29/01/2007 | Pharmaceuticals | 815 | -0.3 | 1.3 | -4.8 | 6.7 | -8.9 | -1.1 | 29.2 | 44.6 | DAILY | 233.45 | 248.94 | 242.19 | 243.08 | 238.63 | 242.86 | 239.69 | 237.12 | 236.81 | 232.37 | 1 | False | False | 1.99 | NA | False | False | False | 69.7 | Healthcare | 56.9 | False | False | False | False | False | False | 5.2 | False | 5 | 0.52 | 0.8 | 2.5 | 1.8 | False | 42856.15 | 139962.6 | 102654.98 | 81781.48 | 51864.18 | False | 37.9 | 68.94 | 66.25 | 66.33 | 17.6 | 4.2 | 4.7 | 4.7 | 4.7 | 33.6 | 33.6 | 29.2 | NA | 0.6 | False,False;False,False;False,False | [False, False, False] | ['2025-05-16', 329.7, '2026-01-27', 161.5] | 271.81 | Dec 2025:05/02/2026,Sep 2025:13/11/2025,Jun 2025:04/08/2025 | Wanbury Limited | -10.4 | 9 | Jun 2025:NA,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/ef453e53-0e5a-486c-a99a-0d753a244170.pdf | 8.5 | 8.5 | 9.6 | 17.9 | 15.76 | 15.18 | 13.49 | 20.26 | 1.22 | 8.02 | 1.04 | 33.63 | 3.8 | 1191.8 | 4.52 | 4.35 | 4.1 | 6.18 | 0.37 | 2.45 | 0.32 | 10.27 | 3.9 | 1121.6 | 9.32 | 9.28 | 162.45 | 160.06 | 163.18 | 172 | 133.45 | 161.19 | 131.11 | 139.41 | 1.5 | 21.7 | 10.29 | 16.42 | 16.11 | 14.98 | 17.23 | 10.45 | 12.41 | 8.37 | 13.03 | 1.9 | 57.1 | Dec 2025 | 66.87 | 33.93 | 1.83 | 16.2 | 12.2 | -0.1 | 0 | 3.45 | 0.17 | 12.91 | 27.82 | Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India. **Website:** [https://www.wanbury.com](https://www.wanbury.com) | 43.08 | 56.21 | 0.72 | 0 | 39.63 | 0.82 | 0 | 7.6 | 991.13 | 9.08 | 1.51 | ||||||||
| 1 | 98 | 96 | 98 | 26/07/2010 | Pharmaceuticals | 2687 | 0.6 | 8.5 | 24.4 | 44.9 | 61.2 | 118.3 | 4.1 | 133 | DAILY | 254.07 | 171.96 | 175.56 | 210.31 | 220.03 | 176.66 | 210.27 | 224.6 | 225.24 | 234.36 | 48.6 | True | True | 6.84 | NA | True | False | False | 139.8 | Healthcare | 64.6 | False | False | False | False | False | False | 5.2 | False | 20 | 1.46 | 31.8 | 40.9 | 56.5 | False | 2159917.35 | 2816268.94 | 2794643.3 | 2939930.52 | 2452189.92 | False | 10.1 | 97.38 | 98.15 | 98.32 | 1 | 5.2 | 5.7 | 5.7 | 5.4 | 76 | 76 | 4.1 | NA | 0.2 | True,True;True,True;True,True | [True, False, False] | ['2026-04-09', 264.9, '2025-05-09', 109.0] | 254.07 | Dec 2025:10/02/2026,Sep 2025:06/11/2025,Jun 2025:29/07/2025 | Bliss GVS Pharma Limited | 22.1 | 27.3 | Jun 2025:NA | 11.9 | 16.8 | 19.2 | 27.1 | 24.78 | 28.59 | 44.36 | 16.65 | 25.8 | 25.69 | 22.11 | -4.92 | -13.3 | -4 | 2.2 | 2.58 | 4.08 | 1.47 | 2.26 | 2.31 | 1.97 | -0.87 | -14.7 | -2.7 | 8 | 7.21 | 218.25 | 244.4 | 207.47 | 197.99 | 210.42 | 217.68 | 183.64 | 198.13 | -10.7 | 3.7 | 3.27 | 15.94 | 17.79 | 19.92 | 10.65 | 14.15 | 19.06 | 18.69 | 14.31 | -10.4 | 12.7 | Dec 2025 | 8.36 | 11.72 | 0.05 | 16.21 | 24.6 | 1.27 | -0.2 | -0.03 | 0.55 | 28.87 | 14.71 | Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, soaps, sprays, and vaginal washes. In addition, the company offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials, anti-microbials, anti-migraines, anti-oxidants, anti-protozoals, anti-pyretics, anti-septics, anti-spasmodics, anti-ulcers, and anti-ulcerants; cough syrups and nasal decongestants; and products for erectile dysfunction, laryngitis, and pharyngitis. Further, it provides and anti-dandruff shampoos, appetizers, hand sanitizers, health and nutritional supplements, insecticides, mosquito repellants, moisturizers, prickly heat powders, skin lightening lotions, vaginal contraceptives, vaginal hygiene products, and vitamin supplements; and amino acid preparations, iron tonics, antitussives, appetite stimulants, anti-allergics, body supplements, ear wax solvents, and oral rehydration products. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India. **Website:** [https://www.blissgvs.com](https://www.blissgvs.com) | 35.36 | 44.32 | 14.54 | 5.78 | 35.39 | 13.27 | 5.98 | 2.37 | 2543.16 | 11.82 | 2.93 | ||||||||
| 2 | 98 | 76 | 99 | 16/03/2017 | Pharmaceuticals | 1273 | 5.9 | 11.1 | 9.4 | 50.6 | 61.9 | 137 | 2 | 153.8 | DAILY | 572.35 | 397.66 | 415.22 | 490.32 | 529.39 | 412.83 | 495.75 | 524.14 | 524.98 | 532.89 | 4.2 | True | True | 1.05 | NA | True | False | False | 288.1 | Healthcare | 47.1 | False | False | False | False | False | False | 7.9 | False | 20 | 1.71 | 1.9 | 2.8 | 1.7 | False | 78660.95 | 121379.84 | 64292.86 | 98058.55 | 87991.53 | False | 0 | 97.06 | 98.16 | 98.38 | 0 | 5.1 | 5 | 5.4 | 6 | 88.8 | 88.8 | 2 | NA | 1.2 | True,True;True,True;True,True | [False, False, True] | ['2026-04-09', 584.0, '2025-04-09', 225.5] | 572.35 | Dec 2025:05/02/2026,Sep 2025:07/11/2025,Jun 2025:25/07/2025 | Sakar Healthcare Limited | 31.7 | 34.3 | Jun 2025:NA,Sep 2025:https://nsearchives.nseindia.com/corporate/SAKAR_11112025112506_Announcement_-_Investor_Presentation.pdf,Dec 2025:https://nsearchives.nseindia.com/corporate/SAKAR_10022026123511_Announcement_-_Investor_Presentation1.pdf | 12 | 15.7 | 16.6 | 16.6 | [578.1, '23/02/2026', 'DAILY'][578.1, '23/02/2026', 'WEEKLY'] | 10.25 | 4.54 | 4.67 | 5.76 | 4.53 | 4.8 | 2.41 | 3.12 | 125.8 | 126.3 | 4.61 | 2.04 | 2.1 | 2.62 | 2.06 | 2.21 | 1.11 | 1.43 | 126 | 123.8 | 7.97 | 5.37 | 70.34 | 57.56 | 52.74 | 50.24 | 43.42 | 42.78 | 41.15 | 43.06 | 22.2 | 62 | 16.43 | 26.44 | 19.74 | 24.1 | 31.29 | 27.08 | 26.88 | 26 | 25.48 | 33.9 | -2.4 | Dec 2025 | 6.48 | 8.54 | 0.24 | 25.29 | 50.3 | -0.26 | -0.07 | 0 | 9.56 | 31.04 | 37.4 | Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India. **Website:** [https://www.sakarhealthcare.com](https://www.sakarhealthcare.com) | 52.86 | 22.73 | 13.05 | 11.36 | 52.86 | 13.31 | 11.43 | 4.2 | 1345.34 | 22.17 | 5.83 | |||||||
| 3 | 97 | 46 | 99 | 01/07/2002 | Pharmaceuticals | 1243 | -4.7 | 3.2 | 2.5 | 58.5 | 39.7 | 73.2 | 8.7 | 108.4 | DAILY | 143.23 | 109.96 | 111.46 | 135.1 | 140.53 | 114 | 132.96 | 139.84 | 139.98 | 141.19 | 9.9 | True | True | 4.94 | NA | True | False | False | 216.3 | Healthcare | 56.9 | False | False | False | False | False | False | 9.4 | False | 20 | 3.54 | 7.3 | 9.1 | 5.5 | False | 693520.25 | 873431.44 | 462600.75 | 787307.34 | 985898.91 | False | 0 | 93.28 | 96.46 | 96.89 | 0 | 6.5 | 6.1 | 5.7 | 5.8 | 61.6 | 61.6 | 47.9 | NA | 0.8 | True,True;True,True;False,False | [True, False, True] | ['2026-04-09', 156.8, '2025-05-09', 68.7] | 150.28 | Dec 2025:31/01/2026,Sep 2025:14/11/2025,Jun 2025:13/08/2025 | Ind-Swift Laboratories Limited | 26.3 | 38.3 | Jun 2025:NA,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachHis/1aea0d8d-53f1-4c67-9417-9110bc29ff21.pdf | 12.6 | 15 | 16.8 | 16.8 | 9.54 | 7.99 | 8.77 | 222.27 | -5.49 | 0.41 | 0.94 | 493.68 | 19.4 | 273.8 | 1.17 | 0.98 | 1.45 | 36.67 | -0.93 | 0.07 | 0.16 | 83.55 | 19.4 | 225.8 | 41.32 | 91.18 | 150.85 | 152.64 | 152.73 | 138.24 | 128.8 | 11.96 | 33.17 | 528.57 | -1.2 | 17.1 | -6.35 | 2.76 | 0.96 | 2.36 | -6.66 | -5.16 | -98.66 | -29.36 | 17.26 | 187.5 | 153.5 | Dec 2025 | 0.18 | 0.78 | 0.02 | 0.01 | 3.6 | -1 | -0.52 | 3.56 | 2.42 | 30.6 | 16.65 | Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is headquartered in Manimajra, India. **Website:** [https://www.indswiftlabs.com](https://www.indswiftlabs.com) | 43.06 | 42.99 | 13.8 | 0.16 | 39.5 | 14.8 | 0.68 | 0.89 | 861.58 | 13.35 | 1.45 | ||||||||
| 4 | 97 | 72 | 94 | 28/02/2007 | Pharmaceuticals | 3886 | 4 | 6.9 | 8.2 | 22.4 | 52.8 | 108 | 4.4 | 110.3 | DAILY | 415 | 297.14 | 317.23 | 363.55 | 389.26 | 312.69 | 368.64 | 387.02 | 387.66 | 394.11 | 17.6 | False | False | 2.99 | NA | False | False | False | 109 | Healthcare | 31.9 | False | False | False | False | False | False | 5.9 | False | 20 | 1.14 | 8.6 | 8.1 | 10.4 | False | 446472.2 | 429387.92 | 485650.83 | 441721.06 | 393273.33 | False | 17.1 | 96.59 | 97.2 | 97.16 | 1 | 4.4 | 5.1 | 5.4 | 5.1 | 92.8 | 92.8 | 4.4 | NA | 0.2 | True,True;True,True;True,True | [False, False, False] | ['2026-03-11', 433.9, '2025-04-09', 197.4] | 420.3 | Dec 2025:07/02/2026,Sep 2025:08/11/2025,Jun 2025:09/08/2025 | SMS Pharmaceuticals Limited | 30.5 | 36.4 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf3dc633-7f8c-461c-958a-0758bcb8d10d.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=faca478f-827d-419a-a4dc-966a097596e8.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/33df2677-efab-49bb-8997-d75763fea5db.pdf | 8.8 | 11.8 | 11.8 | 17.9 | 23.34 | 25.14 | 18.21 | 20.62 | 17.17 | 14.26 | 16.33 | 15.92 | -7.2 | 35.9 | 2.49 | 2.68 | 2.05 | 2.33 | 2.03 | 1.68 | 1.93 | 1.88 | -7.1 | 22.7 | 7.71 | 5.83 | 210.45 | 242.43 | 196.05 | 248.2 | 173.35 | 196.75 | 164.45 | 245.8 | -13.2 | 21.4 | 13.7 | 20.81 | 19.96 | 19.82 | 16.66 | 19.21 | 16.2 | 20.35 | 13.62 | 4.3 | 8.3 | Dec 2025 | 11 | 12.19 | 0.43 | 19.22 | 43.4 | -0.24 | 0.33 | 0 | 278.69 | 41.67 | 32.07 | SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. The company offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India. **Website:** [https://smspharma.com](https://smspharma.com) | 68.06 | 28.69 | 0.04 | 3.21 | 68.06 | 0.28 | 2.88 | 5.11 | 4119.17 | 22.94 | 4.59 | ||||||||
| 5 | 95 | 80 | 97 | 16/10/2025 | Pharmaceuticals | 14105 | 7.2 | 10.5 | 11.1 | 31.6 | 36.3 | 36.3 | 0.9 | 50 | DAILY | 856.2 | NA | NA | 766.28 | 779.24 | NA | 759.83 | 782.4 | 783.13 | 793.42 | 15.1 | True | True | 6.59 | NA | True | False | False | NA | Healthcare | 40 | False | False | False | False | False | False | 7.9 | False | 20 | 3.66 | 12.5 | 13.5 | 17.9 | False | 190779.75 | 207067.58 | NA | 439677.93 | 226604.21 | False | NA | 92.93 | 93.82 | 94.1 | 1.1 | 3.7 | 3.5 | 3.7 | 3.6 | 72 | 72 | 0.9 | NA | -0.1 | False,False;False,False;False,False | [True, False, True] | ['2026-04-09', 864.0, '2025-10-24', 570.8] | 856.2 | Dec 2025:03/02/2026,Sep 2025:13/11/2025 | Rubicon Research Limited | 18.6 | 19.7 | Jun 2025:NA,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07a97ce1-1340-46b8-95bd-92f0092cc909.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/bb38d485-1743-4c3e-b8f1-f32a24b1dd45.pdf | 10.9 | 11.8 | 12.5 | 13.9 | 72.8 | 53.85 | 43.3 | NA | 38.07 | 34.48 | NA | NA | 35.2 | 91.2 | 4.42 | 3.49 | 2.81 | NA | 2.5 | 2.27 | NA | NA | 26.6 | 76.8 | 8.72 | 5.98 | 475.53 | 412.02 | 352.49 | NA | 313.4 | 296.01 | NA | NA | 15.4 | 51.7 | 37.32 | 22.74 | 22.89 | 22.45 | NA | 22.3 | 20.83 | NA | NA | -0.7 | 2 | Dec 2025 | 28.88 | 26.05 | 0.88 | 19.93 | 98.2 | 0 | 0 | 0 | 1.43 | 48.43 | 89.32 | NA | 59.99 | 22.57 | 7.99 | 9.45 | 59.99 | 7.99 | 9.45 | 21.79 | 14522.03 | 54.4 | 11.31 | ||||||||
| 6 | 93 | 97 | 69 | 12/11/2012 | Pharmaceuticals | 322 | 10 | 22.3 | 27.2 | -1.3 | -16.2 | 87.8 | 32.6 | 90.2 | DAILY | 136.13 | 124.2 | 135.78 | 114.59 | 113.76 | 119.87 | 118.17 | 115.9 | 116 | 118.74 | 0.1 | True | False | 0.59 | NA | False | False | True | 54.2 | Healthcare | 25 | False | False | False | False | True | 27/03/2026 | False | 6.7 | False | 10 | 1.96 | 0.1 | 0.1 | 0 | False | 5000.75 | 4121.32 | 6729.91 | 4650.93 | 4715.12 | False | 47.1 | 93.54 | 92.78 | 91.98 | 4.1 | 4.2 | 5.3 | 5 | 5.3 | 37.6 | 37.6 | 41.7 | NA | 5 | True,False;True,False;True,False | [True, False, False] | ['2025-11-12', 202.1, '2025-05-09', 71.6] | 136.13 | Dec 2025:11/02/2026,Sep 2025:11/11/2025,Jun 2025:12/08/2025 | Bafna Pharmaceuticals Limited | 6.1 | 6.1 | Jun 2025:NA | 16.4 | 19.9 | 20.4 | 30.4 | 1.84 | 3.12 | 3.39 | 1.31 | 0.95 | 2.62 | -0.72 | 1.46 | -41 | 93.7 | 0.78 | 1.32 | 1.43 | 0.55 | 0.4 | 1.11 | -0.3 | 0.62 | -40.9 | 95 | 1.75 | 3.11 | 38.29 | 35.47 | 34.62 | 39.06 | 33.19 | 40.32 | 33.29 | 41.4 | 8 | 15.4 | 27.99 | 7.97 | 12.07 | 14.64 | 7.96 | 9.22 | 9.4 | 3.63 | 6.98 | -34 | -13.6 | Dec 2025 | 7.69 | 8.34 | 0.36 | 10.52 | 33.4 | 0 | 0 | 0 | -6.03 | 43.63 | 34.16 | Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, and internationally. The company was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited operates as a subsidiary of SRJR Lifesciences LLP. **Website:** [https://www.bafnapharma.com](https://www.bafnapharma.com) | 75 | 15.66 | 9.34 | 0 | 75 | 9.34 | 0 | 3.53 | 362.76 | 18.56 | 2.46 | |||||||
| 7 | 93 | 61 | 80 | 10/07/2024 | Pharmaceuticals | 30427 | 2.5 | 3.7 | 5.5 | 4.2 | 15 | 77.2 | 4 | 78.3 | DAILY | 1604.9 | 1415.77 | 1429.4 | 1497.94 | 1539.62 | 1418.42 | 1508.53 | 1541.44 | 1543.21 | 1565.17 | 44 | False | False | 4.2 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 127 | Healthcare | 22.1 | False | False | False | False | False | False | 3 | False | 10 | 0.74 | 37.9 | 34.4 | 33.5 | False | 280594.1 | 256239.88 | 418103.51 | 278699.31 | 296611.42 | False | 82.3 | 89.37 | 92.13 | 92.61 | 0 | 3.7 | 4.1 | 4 | 4.1 | 72.8 | 72.8 | 4 | NA | 0.3 | True,True;True,True;True,True | [False, False, False] | ['2026-03-27', 1671.8, '2025-04-09', 900.0] | 1652.7 | Dec 2025:04/02/2026,Sep 2025:11/11/2025,Jun 2025:07/08/2025 | Emcure Pharmaceuticals Limited | 4.6 | 8.9 | Jun 2025:NA,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d68fbde8-815b-4168-9eed-97c965b6ad1a.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/138b3053-0954-4056-b45a-a77eeece8604.pdf | 4.4 | 9.8 | 12.4 | 15.1 | ['WEEKLY', '2026-04-06', '2026-03-30', '2026-03-23'] | 231.37 | 251.37 | 214.79 | 197.24 | 156.09 | 201.55 | 152.59 | 121.02 | -8 | 48.2 | 12.16 | 12.84 | 10.92 | 9.97 | 8.11 | 10.29 | 7.95 | 6.36 | -5.3 | 49.9 | 35.96 | 27.5 | 2363.48 | 2269.82 | 2100.54 | 2116.25 | 1962.63 | 2001.98 | 1815.14 | 1771.36 | 4.1 | 20.4 | 9.36 | 20.85 | 20.95 | 19.84 | 19.02 | 18.07 | 19.03 | 18.53 | 17.58 | -0.5 | 15.4 | Dec 2025 | 18.51 | 20.72 | 0.35 | 20.2 | 35 | 0.3 | 1.74 | -0.01 | 30.61 | 33 | 35.57 | Emcure Pharmaceuticals Limited engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. It offers products in various therapeutic areas, such as gynecology, cardiovascular, anti-infectives, HIV antivirals, respiratory, gastrointestinal, pain and analgesics, blood related, oncology/anti-neoplastics, anti-diabetic, hormones, neurology/central nervous system, dermatology, and other areas, as well as vitamins, minerals, and nutrients. The company also develops products across various platforms, including chiral molecules, complex APIs, orals, iron products, photo-chemistry products, liposomal and lyophilized injectables, high potency drugs, biotherapeutics, and novel drug delivery systems. It provides its products under Orofer, Bevon, Maxtra, Zostum, Metpure, and Eslo brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India. **Website:** [https://www.emcure.com](https://www.emcure.com) | 77.87 | 12.43 | 3.59 | 6.1 | 77.88 | 3.29 | 4.36 | 6.42 | 31614.4 | 17.56 | 3.57 | |||||||
| 8 | 91 | 45 | 85 | 01/07/2002 | Pharmaceuticals | 61212 | -0.2 | 3.7 | 2.4 | 8.1 | 12.1 | 57.6 | 5.6 | 62.4 | DAILY | 2169.1 | 1992.52 | 1998.5 | 2077.8 | 2156.03 | 1943.01 | 2093.37 | 2131.39 | 2132.44 | 2138.64 | 158.9 | False | False | 15.06 | Nifty Pharma,Nifty Healthcare,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | 66.2 | Healthcare | 53.3 | False | False | False | False | True | 10/03/2026 | True | 2 | True | No Band | 0.83 | 47.9 | 37.1 | 45.1 | True | 734146.05 | 572196.96 | 740282.83 | 623320.09 | 656497.43 | False | 32.6 | 91.31 | 90.74 | 90.11 | 2.2 | 3.6 | 3.7 | 3.6 | 3.3 | 64 | 64 | 5.6 | NA | 0 | True,True;True,True;True,True | [True, False, False] | ['2026-03-11', 2297.9, '2025-04-17', 1336.0] | 2272.7 | Dec 2025:30/01/2026,Sep 2025:14/11/2025,Jun 2025:14/08/2025 | Glenmark Pharmaceuticals Limited | 7.6 | 14 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6139070-f93f-4e0b-b520-cdcf5431009a.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56fa1426-7a72-499d-8b43-3b4d1fad129f.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/856749e4-3647-45da-8001-1814468ab0bc.pdf | 5.4 | 10.1 | 12.1 | 14.4 | [2203.9, '08/09/2025', 'WEEKLY'] | ['DAILY', '2026-04-09', '2026-04-08']['WEEKLY', '2026-04-06', '2026-03-30'] | 403.23 | 610.43 | 46.97 | 4.38 | 348.03 | 354.48 | 340.24 | -1214.27 | -33.9 | 15.9 | 14.29 | 21.63 | 1.66 | 0.16 | 12.33 | 12.55 | 12.06 | -43.17 | -33.9 | 15.9 | 37.11 | -53.22 | 3900.62 | 6046.87 | 3264.44 | 3256.2 | 3387.55 | 3433.8 | 3244.18 | 3062.96 | -35.5 | 15.1 | 4.6 | 22.3 | 39.02 | 17.78 | 17.23 | 17.72 | 17.53 | 18.13 | 16.47 | -42.8 | 25.8 | Dec 2025 | 15.79 | 19.4 | 0.13 | 26.54 | 57.5 | -1.53 | 1.48 | 0 | 3.62 | 37.95 | 18.82 | Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India. **Website:** [https://www.glenmarkpharma.com](https://www.glenmarkpharma.com) | 46.65 | 14.02 | 19.2 | 20.09 | 46.65 | 20.73 | 18.61 | 6.39 | 59722.18 | 12.83 | 3.63 | |||||
| 9 | 91 | 87 | 82 | 26/06/2002 | Pharmaceuticals | 9182 | 3.3 | 2.6 | 15 | 5.8 | 16.9 | 70.5 | 2.8 | 75.8 | DAILY | 996.25 | 882.7 | 885.95 | 886.22 | 928.68 | 857.52 | 907.23 | 934.4 | 936.25 | 961.25 | 27.1 | True | True | 6.65 | NA | False | False | False | 51.5 | Healthcare | 72.1 | False | False | False | False | False | False | 4.6 | False | 20 | 0.91 | 9.2 | 12 | 10.8 | False | 291763.55 | 382960.48 | 446751.33 | 321792.4 | 287073.11 | False | 42.1 | 92.17 | 91.15 | 90.92 | 5.2 | 4.1 | 3.7 | 3.6 | 3.3 | 52 | 52 | 2.8 | NA | -0.2 | True,True;True,True;True,False | [False, False, False] | ['2025-11-03', 1025.0, '2025-04-09', 566.7] | 996.25 | Dec 2025:30/01/2026,Sep 2025:31/10/2025,Jun 2025:29/07/2025 | Strides Pharma Science Limited | 13.6 | 15 | Jun 2025:https://www.bseindia.com/xml-data/corpfiling/AttachHis/97a20ca8-f543-4456-91e9-a60daa8508c0.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b5e15d98-b7ee-4831-a7ba-e622041afc97.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/3ada5c53-065b-4cf6-a49a-8e35f2171226.pdf | 5.1 | 8.3 | 10.2 | 14.2 | [1002.6, '03/11/2025', 'DAILY'][1002.6, '03/11/2025', 'WEEKLY'] | ['DAILY', '2026-04-09', '2026-04-08'] | 208.13 | 131.52 | 105.6 | 85.61 | 90.04 | 72.27 | 3349.58 | 10.45 | 58.2 | 131.2 | 21.93 | 13.84 | 10.8 | 8.91 | 9.54 | 7.81 | 364.69 | 1.98 | 58.5 | 129.9 | 389.75 | -7.68 | 1194.65 | 1220.83 | 1119.74 | 1190.39 | 1153.67 | 1166.93 | 1054.34 | 1043.5 | -2.1 | 3.6 | 10.65 | 19.75 | 18.88 | 19.48 | 18.3 | 18.23 | 15.76 | 17.87 | 16.23 | 4.6 | 8.3 | Dec 2025 | 150.67 | 14.68 | 0.67 | 19.1 | 18 | 1.01 | 0.04 | 0.01 | 0.11 | 11.36 | 22.95 | Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India. **Website:** [https://www.strides.com](https://www.strides.com) | 27.87 | 29.59 | 29.52 | 13.02 | 27.86 | 28.51 | 12.98 | 3.33 | 10858.07 | 10.24 | 2.3 | ||||||
| 10 | 91 | 17 | 82 | 18/12/2024 | Pharmaceuticals | 20714 | 0.5 | 1.9 | -3.8 | 5.9 | 14.9 | 52.8 | 9.8 | 53.8 | DAILY | 978.1 | 882.73 | 903.98 | 945.32 | 985.41 | 885.78 | 956.18 | 975.91 | 976.18 | 972.88 | 55.7 | False | False | 13.83 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 81.2 | Healthcare | 65.3 | False | False | False | False | False | False | 3.2 | False | 20 | 1.21 | 45.2 | 56 | 39.8 | False | 563717.5 | 702979.22 | 2543489.37 | 617314.9 | 588954.16 | False | 88.6 | 88.93 | 89.49 | 89.4 | 0 | 3.3 | 3.5 | 3.7 | 3.8 | 70.4 | 70.4 | 9.8 | NA | -0.1 | True,True;True,True;True,True | [True, False, False] | ['2026-03-05', 1084.0, '2025-04-09', 636.1] | 1069.2 | Dec 2025:05/02/2026,Sep 2025:06/11/2025,Jun 2025:07/08/2025 | Sai Life Sciences Limited | 20.6 | 33.7 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8346dc33-3f76-4839-81bf-2266e198b181.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7cf0f8c-4a34-4d16-b7f6-ee9ebf053c02.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/036de689-8dd4-46da-ae7d-be82aedbcfc4.pdf | 6.9 | 6.9 | 8.7 | 11.2 | 100.38 | 83.84 | 60.46 | 88.27 | 53.85 | 41.51 | -13.5 | 61.5 | 19.7 | 86.4 | 4.75 | 4 | 2.9 | 4.24 | 2.59 | NA | NA | NA | 18.8 | 83.4 | 8.16 | NA | 556.46 | 537.47 | 496.42 | 579.51 | 439.78 | 395.56 | 279.72 | 427.54 | 3.5 | 26.5 | 18.49 | 33.76 | 27.13 | 24.36 | 27.19 | 27.23 | 25.84 | 9.34 | 29.6 | 24.4 | 24 | Dec 2025 | 11.05 | 14.05 | 0.18 | 28.21 | 61.6 | -1.09 | 1.49 | -0.23 | 0.27 | 51.48 | 62.78 | Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. The company offers medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India. **Website:** [https://www.sailife.com](https://www.sailife.com) | 34.7 | 12.49 | 21.41 | 31.41 | 34.93 | 22.5 | 29.92 | 9.1 | 20845.7 | 31.81 | 9.61 | ||||||||
| 11 | 91 | 74 | 71 | 30/12/2024 | Pharmaceuticals | 3708 | 2.8 | 2.7 | 8.7 | -0.7 | 11.8 | 56.2 | 8.1 | 69.5 | DAILY | 805.35 | 736.98 | 771.28 | 778.11 | 758.53 | 734.02 | 774.8 | 769.49 | 769.61 | 776.53 | 13.7 | True | False | 2.5 | NA | False | False | False | 51.1 | Healthcare | 54.2 | False | False | False | False | False | False | 3.5 | False | 20 | 3.07 | 11 | 10.1 | 14.8 | False | 177595.4 | 162648.84 | 910537.69 | 206609.18 | 219235.53 | False | 88.2 | 91.3 | 90.72 | 90.27 | 3.2 | 3.7 | 3.9 | 3.7 | 3.7 | 71.2 | 71.2 | 8.1 | NA | 2.1 | True,True;True,False;True,False | [True, False, False] | ['2026-01-07', 876.5, '2025-05-09', 475.0] | 838.15 | Dec 2025:20/01/2026,Sep 2025:06/11/2025,Jun 2025:23/07/2025 | Senores Pharmaceuticals Limited | 2.7 | 8.6 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac708ea4-5002-47b3-9d76-4bc491661e1f.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce4efec9-6bad-4249-90d2-721dcdb9caae.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/1e0dcb04-9670-4851-a381-cf5c0a5d34fd.pdf | 6.6 | 9.3 | 9.3 | 13.7 | [811.7, '23/02/2026', 'DAILY'] | 33.58 | 30.12 | 21.18 | 17.97 | 16.43 | 13.07 | 10.91 | 14.18 | 11.5 | 104.4 | 6.87 | 7.03 | 4.28 | 3.87 | 3.73 | 3.86 | 3.23 | 5.23 | -2.3 | 84.2 | 12.72 | 10.31 | 174.56 | 161.76 | 137.99 | 114.21 | 103.02 | 100.63 | 80.39 | 102.44 | 7.9 | 69.4 | NA | 30.94 | 30.61 | 24.76 | 17.02 | 24.94 | 23.12 | 26.52 | 21.86 | 1.1 | 24.1 | Dec 2025 | 11.82 | 11.4 | 0.3 | 26.7 | 36.5 | 0.29 | 0.3 | 0.01 | 0.13 | 29.31 | 43.42 | Senores Pharmaceuticals Limited develops, manufactures, and sells, pharmaceutical products in India, the United States, Canada, and internationally. The company offers tablets, capsules, liquids, dry syrups, oral rehydration solutions, active pharmaceutical ingredients, and critical care injectables, including antibiotics, anti-bacterial, anti-fungal, and blood line. It also exports its products. The company provides consulting and licensing services. Senores Pharmaceuticals Limited was incorporated in 2017 and is based in Ahmedabad, India. **Website:** [https://senorespharma.com](https://senorespharma.com) | 45.82 | 40.92 | 3.64 | 9.62 | 45.81 | 3.35 | 9.32 | 4.56 | 3746.51 | 20.65 | 6.37 | |||||||
| 12 | 89 | 69 | 89 | 15/01/1996 | Pharmaceuticals | 77850 | 0.4 | 0.5 | 7.5 | 11.8 | 19.7 | 26.7 | 1.7 | 31.9 | DAILY | 1340.4 | 1159.24 | 1176.62 | 1231.62 | 1304.08 | 1192.78 | 1253.42 | 1297.2 | 1299.36 | 1322.62 | 235.5 | False | False | 27.98 | Nifty Pharma,Nifty Healthcare,Nifty Manufacturing,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | 147.3 | Healthcare | 48.2 | False | False | False | False | False | False | 1.9 | True | No Band | 0.52 | 143.5 | 154.8 | 111.1 | False | 1801244.2 | 1951461.42 | 1446543.95 | 1738448.03 | 1830487.29 | False | 0.4 | 84.37 | 87.74 | 88.2 | 0 | 3.3 | 2.9 | 2.8 | 2.9 | 77.6 | 77.6 | 15.8 | NA | -0.1 | True,True;False,True;False,True | [False, False, False] | ['2026-04-08', 1363.0, '2025-09-01', 1016.1] | 1342.1 | Dec 2025:09/02/2026,Sep 2025:05/11/2025,Jun 2025:04/08/2025 | Aurobindo Pharma Limited | 11.4 | 13.2 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8315ee0f-ddb9-4da4-808f-ca32938618e5.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3f251a0-a55f-47f8-88cf-8e712f9ff554.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/04527598-c3a8-4c8c-a952-b486638c9178.pdf | 3.4 | 7.1 | 7.1 | 9 | [1362.7, 1330.0, '06/04/2026', 'DAILY'] | ['DAILY', '2026-04-09', '2026-04-08'] | 909.8 | 848.13 | 824.2 | 902.83 | 845.57 | 816.95 | 918.22 | 907.35 | 7.3 | 7.6 | 15.67 | 14.61 | 14.2 | 15.42 | 14.56 | 14.07 | 15.69 | 15.51 | 7.3 | 7.6 | 60.02 | 54.15 | 8645.9 | 8285.7 | 7868.14 | 8382.12 | 7978.52 | 7796.07 | 7567.02 | 7580.15 | 4.3 | 8.4 | 6.55 | 20.51 | 20.25 | 20.37 | 20.99 | 19.78 | 20.09 | 21.38 | 21.9 | 1.3 | 3.7 | Dec 2025 | 11.08 | 14.18 | 0.22 | 20.54 | 22.3 | -0.26 | 0.06 | 0 | 2.79 | 21.38 | 18.78 | Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India. **Website:** [https://www.aurobindo.com](https://www.aurobindo.com) | 51.82 | 6.55 | 13.95 | 27.66 | 51.82 | 14.21 | 27.6 | 2.22 | 76788.74 | 10.42 | 2.31 | ||||||
| 13 | 87 | 10 | 79 | 01/07/2002 | Pharmaceuticals | 138576 | 1.6 | 2.7 | -6.4 | 3.3 | 15.3 | 30.9 | 8.7 | 32 | DAILY | 4094.5 | 3778.28 | 3873.07 | 4189.84 | 4228.82 | 3826.42 | 4157.76 | 4177.47 | 4174.64 | 4116.72 | 169.1 | False | False | 10.73 | Nifty Pharma,Nifty Healthcare,Nifty Manufacturing,Nifty 100,Nifty 500 | False | False | False | 121.1 | Healthcare | 31.7 | False | False | False | False | False | False | 1.8 | True | No Band | 0.9 | 72 | 70.1 | 53 | False | 401733.85 | 395336.6 | 335210.56 | 385419.62 | 424331.19 | False | 20.7 | 87.94 | 88.12 | 87.92 | 3.3 | 3 | 2.8 | 2.6 | 2.6 | 88 | 88 | 8.7 | NA | 0.5 | True,True;True,True;True,True | [False, False, True] | ['2026-03-13', 4482.9, '2025-05-09', 3101.6] | 4446 | Dec 2025:13/02/2026,Sep 2025:07/11/2025,Jun 2025:28/07/2025 | Torrent Pharmaceuticals Limited | 0.4 | 9.9 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6314da61-f7f2-42a3-a461-607c3a8f44ad.pdf,Sep 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/6e94e952-be35-4092-b775-7b3ece9ecce0.pdf | 3.9 | 5.7 | 10.7 | 13.6 | ['WEEKLY', '2026-04-06', '2026-03-30'] | 635 | 591 | 548 | 498 | 503 | 453 | 457 | 449 | 7.4 | 26.2 | 18.76 | 17.46 | 16.19 | 14.71 | 14.86 | 13.38 | 13.5 | 13.27 | 7.4 | 26.2 | 56.47 | 48.94 | 3303 | 3302 | 3178 | 2959 | 2809 | 2889 | 2859 | 2745 | 0 | 17.6 | 7.72 | 32.94 | 32.8 | 32.47 | 32.58 | 32.54 | 32.5 | 31.62 | 32.17 | 0.4 | 1.2 | Dec 2025 | 26.52 | 27.05 | 0.33 | 32.7 | 61 | 0.21 | -0.12 | 0 | 2.84 | 54.56 | 52.4 | Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited. **Website:** [https://www.torrentpharma.com](https://www.torrentpharma.com) | 68.31 | 6.41 | 16.13 | 9.05 | 68.31 | 15.92 | 9.17 | 16.4 | 140748.54 | 34.56 | 11.05 | |||||||
| 14 | 86 | 85 | 93 | 06/08/2021 | Pharmaceuticals | 12795 | -0.2 | 5.4 | 13.4 | 18.5 | 10.4 | 10.8 | 14.9 | 27.3 | DAILY | 1042.55 | 942 | 922.8 | 939.41 | 970.21 | 947.12 | 947.7 | 977.61 | 979.46 | 1005.25 | 8.5 | True | True | 3.08 | NA | False | False | False | 70.1 | Healthcare | 25.1 | False | False | False | False | True | 06/04/2026 | True | 2 | False | 20 | 0.5 | 8.7 | 7.4 | 8.5 | True | 87222.8 | 73212.76 | 98622.69 | 82258.03 | 90910.63 | False | 29.5 | 78.54 | 82.07 | 83.31 | 0 | 4.1 | 3.8 | 3.6 | 3.6 | 40 | 40 | 16.7 | NA | 0.2 | False,False;False,False;False,False | [False, False, False] | ['2025-05-15', 1225.1, '2026-01-22', 819.0] | 1044.25 | Dec 2025:22/01/2026,Sep 2025:06/11/2025,Jun 2025:01/08/2025 | Alivus Life Sciences Limited | 21 | 23.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c28a52f-fa3c-4117-9f2f-6a4cb2351915.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=456b8f18-4155-43de-b301-ca96c323a1de.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/512b006a-0a27-4139-9724-eba7013ba461.pdf | 6.1 | 9.7 | 9.7 | 14.3 | [1053.0, '30/07/2025', 'DAILY'] | 150.26 | 130.03 | 121.54 | 141.87 | 136.96 | 95.32 | 111.48 | 97.94 | 15.6 | 9.7 | 12.25 | 10.6 | 9.91 | 11.58 | 11.18 | 7.78 | 9.1 | 7.99 | 15.6 | 9.6 | 39.63 | 38.43 | 672.89 | 587.98 | 601.85 | 649.55 | 641.84 | 506.88 | 588.62 | 536.6 | 14.4 | 4.8 | 9.2 | 34.37 | 30.47 | 28.63 | 30.55 | 29.65 | 26.51 | 27.1 | 26.36 | 12.8 | 15.9 | Dec 2025 | 18.69 | 24.92 | 0.02 | 31.09 | 23.5 | -1.76 | 1.66 | 0 | 4.83 | 21.28 | 16.01 | Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited. **Website:** [https://www.alivus.com](https://www.alivus.com) | 74.91 | 12.89 | 5.08 | 7.13 | 74.91 | 6.84 | 5.47 | 4.24 | 12849.41 | 15.5 | 5.11 | ||||||
| 15 | 86 | 31 | 81 | 10/09/2001 | Pharmaceuticals | 104927 | 0 | 0.9 | -0.3 | 5.2 | 17.2 | 19.6 | 3.5 | 25 | DAILY | 2295.1 | 2065.94 | 2109.22 | 2258.65 | 2308.04 | 2119.6 | 2259.73 | 2296.39 | 2297.05 | 2297.57 | 257.8 | False | False | 24.28 | Nifty Pharma,Nifty Healthcare,Nifty Manufacturing,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | 100.9 | Healthcare | 53.1 | False | False | False | False | True | 09/04/2026 | True | 1.8 | True | No Band | 1.97 | 127.4 | 110.8 | 105.8 | False | 1116947.15 | 976812.02 | 983840.35 | 1054200.4 | 1224031.57 | False | 13.1 | 84.82 | 86.04 | 86.31 | 2.3 | 3.1 | 2.6 | 2.4 | 2.2 | 87.2 | 87.2 | 4.5 | NA | 0.3 | True,True;True,True;True,True | [False, False, True] | ['2026-03-11', 2377.6, '2025-08-06', 1836.8] | 2357.3 | Dec 2025:12/02/2026,Sep 2025:06/11/2025,Jun 2025:05/08/2025 | Lupin Limited | 3.8 | 7.5 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d1ec720-157a-4541-9887-ee92480f028c.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4bcf95d2-421b-4a61-bfdc-4788a5144f81.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/31389bc5-2400-4652-b0b3-705933d141e5.pdf | 3.9 | 7.2 | 8 | 8.7 | ['DAILY', '2026-04-09', '2026-04-08']['WEEKLY', '2026-04-06', '2026-03-30'] | 1180.51 | 1484.83 | 1221.46 | 782.38 | 858.86 | 859.48 | 805.54 | 368.22 | -20.5 | 37.5 | 25.73 | 32.36 | 26.69 | 16.92 | 18.74 | 18.69 | 17.58 | 7.89 | -20.5 | 37.3 | 71.88 | 42.01 | 7167.52 | 7047.51 | 6268.34 | 5667.13 | 5767.71 | 5672.73 | 5600.33 | 4960.79 | 1.7 | 24.3 | 8.11 | 31.56 | 33.22 | 27.55 | 23.31 | 23.51 | 23.63 | 22.16 | 20.09 | -5 | 34.2 | Dec 2025 | 20.62 | 21.3 | 0.32 | 29.26 | 22.6 | 1 | -0.98 | -0.01 | 0.35 | 22.3 | 40.77 | Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India. **Website:** [https://www.lupin.com](https://www.lupin.com) | 46.89 | 6.04 | 21.5 | 25.58 | 46.9 | 20.5 | 26.56 | 5.34 | 108129.12 | 13.53 | 4.13 | ||||||
| 16 | 85 | 49 | 3 | 19/08/2005 | Pharmaceuticals | 58 | 4.9 | 21.1 | 3.2 | -33.3 | 41.6 | 41.6 | 76.2 | 41.6 | DAILY | 7.01 | 6.69 | 7.26 | 7.12 | 6.3 | 6.99 | 7.16 | 6.43 | 6.41 | 6.29 | 0.1 | False | False | 7.65 | NA | False | False | False | 257.6 | Healthcare | 92.2 | False | False | False | False | False | False | 4.3 | False | 5 | 0.41 | 0.3 | 0.7 | 0.5 | False | 153995.7 | 358729.8 | 183965.54 | 249610.32 | 150224.06 | False | 5 | 90.53 | 87.28 | 82.37 | 11.5 | 4.5 | 4.8 | 4.8 | 5.1 | 12 | 12 | 95.4 | NA | 4.6 | True,False;True,False;True,False | [True, False, False] | ['2025-12-18', 29.4, '2025-04-09', 4.9] | 7.01 | Dec 2025:13/03/2026,Sep 2025:13/11/2025,Jun 2025:13/08/2025 | Vivimed Labs Ltd | 1.9 | 4.5 | Jun 2025:NA | 13 | 24.3 | 26.5 | 28.4 | -16.55 | -7.3 | -5.49 | -5.6 | -5.98 | -5.14 | -15.25 | 5.26 | -126.7 | -176.8 | -2 | -0.88 | -0.66 | -0.68 | -0.72 | -0.62 | -1.84 | 0.63 | -127.3 | -177.8 | -3.85 | -5.48 | 15.99 | 20.61 | 21.39 | 25.61 | 36.51 | 24.77 | 29.37 | 38.62 | -22.4 | -56.2 | -35.71 | -68.36 | -4.61 | -1.31 | -9.64 | 2.88 | -2.58 | -37.45 | -73.72 | -1382.9 | -2473.6 | Dec 2025 | NA | -8.1 | NA | -17.5 | -1.7 | 0 | 0 | 0 | NA | -0.88 | NA | NA | 7.77 | 90.47 | 1.64 | 0 | 7.77 | 1.64 | 0 | NA | 446.58 | -45.48 | 5.34 | ||||||||
| 17 | 83 | 65 | 61 | 11/08/2025 | Pharmaceuticals | 8090 | -0.7 | 7.3 | 6.7 | -4.1 | -16 | 51.3 | 23.4 | 73.1 | DAILY | 650.85 | 668.27 | 706.23 | 644.51 | 603.81 | 630.86 | 636.88 | 614.86 | 614.35 | 616.76 | 25.1 | True | False | 4.52 | NA | False | False | False | 185.4 | Healthcare | 36.4 | False | False | False | False | False | False | 2.3 | False | 20 | 0.32 | 12.2 | 11 | 7.4 | True | 422993.2 | 395810.34 | 274439.22 | 382650.75 | 450529.72 | False | 0.5 | 92.14 | 89.1 | 87.81 | 15.3 | 4.8 | 5.1 | 4.5 | 4.5 | 35.2 | 35.2 | 23.4 | NA | 1.1 | True,False;True,False;True,False | [True, False, False] | ['2025-09-23', 849.5, '2025-05-19', 376.0] | 740.45 | Dec 2025:07/02/2026,Sep 2025:06/11/2025,Jun 2025:14/08/2025 | Jeena Sikho Lifecare Limited | -8.6 | 13.6 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5801b3e-24ef-44c3-862a-5d22b99ca2c1.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=573135a0-2404-4f55-a5c7-aaa4f49ebdf6.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/c592f8f1-eaf8-4d4d-9856-b714671fa718.pdf | 9.7 | 14.7 | 19.3 | 19.3 | 66.73 | 58.79 | 51.31 | 27.35 | 13.21 | 46.88 | 16.14 | 37.38 | 13.5 | 405.1 | 5.37 | 4.73 | 3.53 | 2.2 | 1.06 | 3.77 | 1.3 | 3.01 | 13.5 | 406.6 | 7.3 | 5.57 | 221.66 | 189.85 | 174.29 | 139.02 | 115.69 | 214.13 | 100.04 | 167.05 | 16.8 | 91.6 | 37.81 | 45.48 | 48.5 | 45.21 | 33.61 | 25.59 | 27.68 | 24.64 | 28.77 | -6.2 | 77.7 | Dec 2025 | 37.93 | 50.24 | 0.3 | 43.93 | 39.6 | -0.28 | -0.04 | 0.01 | 0.39 | 30.3 | 48.13 | NA | 63.62 | 29.97 | 6.31 | 0.11 | 63.61 | 6.59 | 0.15 | 22.88 | 8168.6 | 25.22 | 11.27 | ||||||||
| 18 | 83 | 31 | 86 | 15/12/2025 | Pharmaceuticals | 9552 | 0.5 | 4.2 | -0.4 | 9.2 | 8.6 | 8.6 | 8.1 | 16.9 | DAILY | 1561.9 | NA | NA | 1557.81 | 1570.8 | NA | 1545.07 | 1558.12 | 1557.74 | 1547.48 | 6.1 | False | False | 1.9 | NA | False | False | False | NA | Healthcare | 31 | False | False | False | False | False | False | 3.9 | False | 20 | 1.03 | 5.6 | 5.1 | NA | False | 38888.75 | 35205.42 | NA | 642205.88 | 39335.97 | False | NA | 82.96 | 83.25 | 83.66 | 4.6 | 3.8 | 3.8 | 4 | 3.7 | 45.6 | 45.6 | 8.1 | NA | -0.1 | False,False;False,False;False,False | [True, False, False] | ['2026-03-10', 1699.0, '2025-12-23', 1336.6] | 1650.5 | Dec 2025:02/02/2026,Sep 2025:02/01/2026 | CORONA Remedies Limited | 7 | 16.4 | Jun 2025:NA,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/060411a6-2262-4146-a26d-c6eee1d715c6.pdf | 8 | 8 | 9.2 | 13.9 | 41.25 | 52.15 | 46.4 | NA | 44.77 | 42.98 | NA | NA | -20.9 | -7.9 | 6.74 | 8.53 | 7.59 | NA | 7.32 | 7.03 | NA | NA | -21 | -7.9 | 24.37 | 14.8 | 342.42 | 361.13 | 346.54 | NA | 297.69 | 313.87 | NA | NA | -5.2 | 15 | 14.75 | 24.29 | 21.73 | 20.14 | NA | 23.32 | 21.29 | NA | NA | 11.8 | 4.2 | Dec 2025 | 27.55 | 31.47 | 0.1 | 20.12 | 64.1 | 0 | 0 | -3.5 | 0.11 | 57.93 | 62.15 | NA | 69 | 22.41 | 1.84 | 6.77 | 72.5 | 1.84 | 6.77 | 14.49 | 9595.57 | 38.91 | 8.02 | ||||||||
| 19 | 81 | 52 | 81 | 23/12/2021 | Pharmaceuticals | 10273 | -0.7 | 2.4 | 3.7 | 4.7 | 9.8 | 14.7 | 18.1 | 18 | DAILY | 855.75 | 826.89 | 811.93 | 837.24 | 833.32 | 818.88 | 832.96 | 836.95 | 837.11 | 841.28 | 14.1 | False | False | 7.17 | NA | False | False | False | 91.3 | Healthcare | 59.7 | False | False | False | False | True | 09/04/2026 | False | 2.4 | False | 20 | 6.66 | 13.5 | 12.9 | 10.7 | True | 167394.7 | 160299.64 | 195573.4 | 171402.51 | 214053.6 | False | 39.9 | 80.38 | 80.64 | 81.04 | 4.7 | 3.2 | 3.5 | 3.3 | 3.2 | 57.6 | 57.6 | 36.3 | NA | 0 | False,True;False,False;False,False | [False, False, False] | ['2025-05-28', 1045.3, '2025-04-09', 725.2] | 894.6 | Dec 2025:30/01/2026,Sep 2025:31/10/2025,Jun 2025:02/08/2025 | Medplus Health Services Limited | 7.1 | 13.3 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a66676d1-1a3f-4856-a0dc-e53f62e71b71.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7da27c8e-88be-4144-93c4-1325038fd387.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/ccd87e41-b767-4df0-bd3a-34172b6b7657.pdf | 5.9 | 7.3 | 7.7 | 9.6 | [869.6, '18/02/2026', 'DAILY'] | ['DAILY', '2026-04-09', '2026-04-08'] | 57.79 | 55.5 | 42.34 | 51.32 | 45.87 | 38.7 | 14.34 | 33.57 | 4.1 | 26 | 4.82 | 4.63 | 3.54 | 4.29 | 3.83 | 3.24 | 1.2 | 2.79 | 4.1 | 25.8 | 12.56 | 5.48 | 1806.12 | 1679.33 | 1542.63 | 1509.61 | 1561.45 | 1576.17 | 1488.83 | 1490.5 | 7.6 | 15.7 | 16.41 | 8.78 | 8.86 | 8.47 | 9.03 | 8.49 | 7.9 | 6.3 | 7.1 | -0.9 | 3.4 | Dec 2025 | 8.8 | 10.28 | 0.65 | 8.79 | 49.5 | 0.3 | 0.07 | 0.01 | 3.06 | 44.39 | 92.52 | MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, comprising medicines, vitamins, medical devices, and test kits; and offers consumer goods, such as home and personal care products, including toiletries, baby care products, soaps and detergents, and sanitizers. The company also provides wholesale cash and carry; diagnostic, pathological, and laboratory testing services, as well as engages in the contract manufacturing of private label pharmaceuticals. It operates stores in Telangana, Andhra Pradesh, Karnataka, Tamil Nadu, West Bengal, Maharashtra, Orissa, Madhya Pradesh, Chhattisgarh, Kerala, and Puducherry, as well as online platform. The company was incorporated in 2006 and is based in Hyderabad, India. **Website:** [https://www.medplusindia.com](https://www.medplusindia.com) | 40.3 | 16.27 | 16.83 | 26.58 | 40.29 | 16.53 | 26.51 | 5.56 | 10963.66 | 17.1 | 1.68 | |||||
| 20 | 81 | 46 | 88 | 06/08/2024 | Pharmaceuticals | 7739 | -2.6 | -1.5 | 2.5 | 10.6 | 10.4 | 14.7 | 21.1 | 20.1 | DAILY | 491.75 | 473.89 | 455.27 | 472.64 | 484.59 | 485.51 | 474.25 | 484.73 | 485.14 | 489.87 | 8.4 | True | True | 3.89 | NA | False | False | False | 102.4 | Healthcare | 24.7 | False | False | False | False | False | False | 5.6 | False | 10 | 1.33 | 10.8 | 14.3 | 14.5 | False | 172856.35 | 228585.24 | 622751.4 | 203604.29 | 179069.19 | False | 87.1 | 64.3 | 76.9 | 78.98 | 1.2 | 3.9 | 3.9 | 4 | 3.7 | 49.6 | 49.6 | 58.2 | NA | -0.2 | False,False;False,False;False,False | [False, False, False] | ['2025-05-27', 623.0, '2026-01-21', 409.3] | 507.25 | Dec 2025:13/02/2026,Sep 2025:13/11/2025,Jun 2025:08/08/2025 | Akums Drugs and Pharmaceuticals Limited | 9 | 15.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44e60f7d-f557-4681-a14e-aad6f34bbd40.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db6e9ff1-303d-411e-ba00-d9a91ec47848.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/4ea4417e-06c8-48f5-a21d-26289582b859.pdf | 6.1 | 7.7 | 11.8 | 12.1 | 67.68 | 42.69 | 64.69 | 149.61 | 66.31 | 66.66 | 61.21 | -39.47 | 58.5 | 2.1 | 4.21 | 2.59 | 4.03 | 9.38 | 4.14 | 4.14 | 4.08 | -2.89 | 62.5 | 1.7 | 21.49 | -0.28 | 1159.59 | 1017.53 | 1024.03 | 1055.55 | 1010.41 | 1033.09 | 1019.11 | 944.21 | 14 | 14.8 | 11.27 | 12.66 | 9.28 | 12.6 | 8.9 | 12.01 | 11.73 | 12.56 | 0.32 | 36.4 | 5.4 | Dec 2025 | 17.19 | 16.2 | 0.03 | 10.91 | 24.3 | 0.24 | -0.05 | 0 | 0.48 | 29.2 | 23.44 | Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. It offers dosage forms, such as tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form fill seals, topical preparations, eye drops, dry powder injections, rotacaps and gummies, and others. The company operates as pharmaceutical contract development and manufacturing company. It also sells branded pharmaceutical formulations. The company was incorporated in 2004 and is based in Delhi, India. **Website:** [https://www.akums.in](https://www.akums.in) | 75.26 | 6.29 | 1.38 | 14.36 | 75.26 | 1.14 | 14.41 | 2.46 | 6139.87 | 10.67 | 1.44 | ||||||||
| 21 | 79 | 11 | 71 | 01/07/2002 | Pharmaceuticals | 34369 | 1.6 | -1.4 | -6.3 | -0.5 | 13.6 | 11.4 | 14.8 | 18.1 | DAILY | 2751 | 2674.03 | 2681.04 | 2890.99 | 2887.65 | 2728.42 | 2854.34 | 2843.75 | 2840.58 | 2787 | 35.2 | False | False | 4.22 | Nifty Pharma,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | 95.6 | Healthcare | 33.7 | False | False | False | False | False | False | 2.4 | False | 20 | 0.64 | 19.7 | 17.8 | 18.9 | True | 120191.75 | 108866.68 | 120641.95 | 112586.77 | 102458.75 | False | 25.9 | 77.66 | 79.66 | 79.52 | 3.7 | 2.9 | 3.4 | 3.6 | 3.3 | 74.4 | 74.4 | 21.1 | NA | 0.1 | True,False;True,False;True,False | [False, False, False] | ['2026-03-13', 3228.0, '2025-09-30', 2329.9] | 3119.5 | Dec 2025:30/01/2026,Sep 2025:03/11/2025,Jun 2025:28/07/2025 | Ajanta Pharma Limited | -1.1 | 16 | Jun 2025:https://www.ajantapharma.com/images/InvestorPresentationQ1FY2026.pdf,Sep 2025:https://nsearchives.nseindia.com/corporate/PRACHI_03112025133222_BMOutcome03112025.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/62f9a571-200b-4472-bb3f-3a7a1cd649cc.pdf | 3.1 | 4.3 | 6.4 | 16.5 | ['DAILY', '2026-04-09', '2026-04-08'] | 273.77 | 260.19 | 255.34 | 225.26 | 232.88 | 216.48 | 245.77 | 202.72 | 5.2 | 17.6 | 21.91 | 20.83 | 20.44 | 18.03 | 18.64 | 17.33 | 19.68 | 15.82 | 5.2 | 17.5 | 73.68 | 63.7 | 1374.84 | 1353.73 | 1302.65 | 1170.41 | 1146.13 | 1186.64 | 1144.92 | 1054.08 | 1.6 | 20 | 12.43 | 27.8 | 24.22 | 26.97 | 25.39 | 27.99 | 26.22 | 28.85 | 26.4 | 14.8 | -0.7 | Dec 2025 | 24.91 | 32.37 | 0.06 | 26.12 | 33.9 | -0.56 | 0.68 | 0.01 | 3.89 | 31.39 | 33.31 | Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India. **Website:** [https://www.ajantapharma.com](https://www.ajantapharma.com) | 66.25 | 7.2 | 7.97 | 18.58 | 66.24 | 8.53 | 17.9 | 7.97 | 34515.07 | 23.21 | 6.64 | |||||||
| 22 | 79 | 75 | 91 | 21/07/2025 | Pharmaceuticals | 40457 | 4.3 | 9 | 9.1 | 14.4 | -6.8 | -1.4 | 17.5 | 24.4 | DAILY | 720.25 | NA | 693.78 | 658.63 | 656.59 | NA | 662.16 | 666.37 | 666.73 | 674.86 | 23.3 | True | True | 14.22 | Nifty Manufacturing,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | NA | Healthcare | 25.3 | False | False | False | False | False | False | 5.9 | False | 20 | 2.13 | 25.9 | 23.6 | 25.5 | False | 349439.8 | 317799.36 | NA | 388204.81 | 420910.38 | False | NA | 71.79 | 74.57 | 76.37 | 2.5 | 3.2 | 3.2 | 3 | 3.2 | 24 | 24 | 17.5 | NA | -0.4 | False,False;False,False;False,False | [True, False, False] | ['2025-09-18', 873.5, '2026-02-02', 579.2] | 720.25 | Dec 2025:05/02/2026,Sep 2025:08/11/2025,Jun 2025:13/08/2025 | Anthem Biosciences Limited | 13.4 | 15.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3702497f-5880-4170-b1c1-c52828d3c96f.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b25f96c-2dc4-4879-94d3-42e991e95d82.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/1bb2c5d7-de77-42f2-8db1-ba1ea7daa022.pdf | 10.2 | 11.3 | 11.4 | 14.5 | 92.82 | 173.43 | 135.79 | 82.62 | 124.33 | 161.93 | 82.38 | NA | -46.5 | -25.3 | 1.65 | 3.09 | 2.42 | 1.48 | 2.22 | 2.9 | 1.47 | NA | -46.6 | -25.7 | 8.07 | 6.57 | 423.15 | 550.03 | 540.21 | 483.2 | 497.81 | 524.96 | 338.59 | NA | -23.1 | -15 | 23.86 | 37.15 | 39.62 | 35.45 | 40.4 | 32.04 | 37.19 | 35.71 | NA | -6.2 | 15.9 | Dec 2025 | 20.83 | 28.5 | 0.04 | 38.15 | 83.4 | -0.29 | 0.39 | 0 | 22.2 | 109.13 | 76.67 | NA | 74.69 | 16.34 | 1.37 | 7.6 | 74.69 | 1.66 | 7.21 | 14.7 | 40042.9 | 45.48 | 20.06 | ||||||||
| 23 | 78 | 54 | 80 | 02/04/2026 | Pharmaceuticals | 1867 | 0.2 | 4.2 | 4.2 | 4.2 | 4.2 | 4.2 | 4.8 | 5.7 | DAILY | 422.7 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | False | False | 2.16 | NA | False | False | False | NA | Healthcare | 48.8 | True | 02/04/2026 | False | True | 02/04/2026 | False | True | 02/04/2026 | False | 4.4 | False | 20 | NA | NA | NA | NA | False | NA | NA | NA | NA | NA | False | NA | 78.98 | 78.92 | 78.82 | 1.3 | 4.7 | NA | NA | NA | 0 | 0 | 4.8 | NA | 0 | False,False;False,False;False,False | [False, False, False] | ['2026-04-08', 443.9, '2026-04-02', 400.0] | NA | NA | Sai Parenterals Limited | NA | NA | Jun 2025:NA | 8.5 | 9.9 | NA | NA | ['DAILY', '2026-04-09', '2026-04-08'] | NA | 7.77 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2.11 | NA | NA | NA | NA | NA | NA | NA | NA | 5.43 | 6.36 | NA | 86.92 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 18.59 | NA | NA | NA | NA | NA | NA | NA | NA | Dec 2025 | 17.14 | 16.53 | 0.38 | 24.14 | 77.8 | 0 | 0 | 0 | NA | 50.08 | 75.51 | NA | 51.16 | 30.25 | 5.73 | 12.86 | 51.16 | 5.73 | 12.86 | NA | 1923.94 | 48.07 | 11.8 | ||||
| 24 | 77 | 55 | 80 | 20/11/2020 | Pharmaceuticals | 28817 | 1.2 | 3.6 | 4.3 | 4.1 | -10.4 | 25.6 | 17.9 | 30.3 | DAILY | 1749.1 | 1833.77 | 1804.89 | 1755.71 | 1673.54 | 1767.21 | 1725.61 | 1703.57 | 1703 | 1707.56 | 14.6 | False | False | 7.94 | Nifty Pharma,Nifty MNC,Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 41.1 | Healthcare | 48.2 | False | False | False | False | False | False | 1.9 | False | 20 | 0.36 | 16.8 | 31.2 | 29.7 | True | 87164.6 | 161663.92 | 185581.03 | 114351.9 | 84145.43 | False | 47.8 | 74.53 | 75.8 | 75.95 | 3.8 | 3 | 3.3 | 3.2 | 3.2 | 25.6 | 25.6 | 59.8 | NA | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-07-29', 2131.0, '2025-04-09', 1342.0] | 1897.5 | Dec 2025:28/01/2026,Sep 2025:03/11/2025,Jun 2025:05/08/2025 | Gland Pharma Limited | 3.5 | 17.5 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4e532e4-80dd-4d42-a96e-b9c7adccfe7a.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90359eb7-19e0-41c8-b0b9-e9c3541f0a24.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/bf4106eb-8744-48f5-b7e3-2fb0d09d8755.pdf | 4.8 | 5.9 | 5.9 | 12.1 | [1752.3, '27/03/2026', 'DAILY'] | ['DAILY', '2026-04-09', '2026-04-08'] | 261.48 | 183.68 | 215.48 | 186.54 | 204.69 | 163.53 | 143.76 | 192.42 | 42.4 | 27.7 | 15.87 | 11.15 | 13.08 | 11.32 | 12.42 | 9.93 | 8.73 | 11.68 | 42.3 | 27.8 | 42.4 | 46.9 | 1695.36 | 1486.88 | 1505.62 | 1424.91 | 1384.05 | 1405.83 | 1401.71 | 1537.45 | 14 | 22.5 | 16.36 | 25.65 | 21.11 | 24.43 | 24.39 | 26.01 | 21.13 | 18.86 | 23.33 | 21.5 | -1.4 | Dec 2025 | 7.81 | 11.89 | 0.03 | 23.95 | 34 | -0.32 | 0.36 | 0 | -1.99 | 27.55 | 39.22 | Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd. **Website:** [https://www.glandpharma.com](https://www.glandpharma.com) | 51.83 | 7.62 | 7.58 | 32.99 | 51.83 | 7.9 | 32.63 | 3.01 | 26404.2 | 15.41 | 4.32 | ||||||
| 25 | 75 | 14 | 71 | 01/01/1996 | Pharmaceuticals | 411989 | 0.1 | 1.4 | -5 | -0.7 | 3.5 | 3.9 | 7.2 | 10.9 | DAILY | 1717.1 | 1697.15 | 1709.48 | 1730.09 | 1763.37 | 1715.25 | 1740.94 | 1744.55 | 1744.1 | 1730.99 | 518.1 | False | False | 109.22 | Nifty Pharma,Nifty Healthcare,Nifty Manufacturing,Nifty 100,Nifty 50,Nifty 500 | False | False | False | 105.4 | Healthcare | 45.5 | False | False | False | False | False | False | 1.6 | True | No Band | 1.11 | 246.2 | 236.3 | 203.5 | True | 2946891.55 | 2847509.24 | 2484377.67 | 2837918.51 | 3136316.93 | False | 0 | 74.28 | 74.93 | 75.01 | 5.1 | 3 | 2.6 | 2.3 | 2.2 | 72.8 | 72.8 | 12.4 | NA | -0.7 | True,False;False,False;False,False | [False, False, False] | ['2025-05-02', 1851.2, '2025-09-26', 1548.0] | 1825.9 | Dec 2025:31/01/2026,Sep 2025:05/11/2025 | Sun Pharmaceutical Industries Limited | 7.6 | 15.5 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=811dac05-9dcf-4c75-8db4-54806ab875d4.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/8ef19f3e-b9ef-4842-9ad9-d0b0120afe72.pdf | 3.9 | 7.4 | 9.5 | 12.1 | ['DAILY', '2026-04-09', '2026-04-08']['WEEKLY', '2026-04-06', '2026-03-30'] | 3381.17 | 3124.95 | 2292.87 | 2153.93 | 2912.98 | 3037.33 | 2860.51 | 2658.74 | 8.2 | 16.1 | 14.04 | 13 | 9.5 | 8.96 | 12.1 | 12.67 | 11.82 | 11.06 | 8 | 16 | 45.55 | 39.91 | 15520.54 | 14478.31 | 13851.4 | 12958.84 | 13675.46 | 13291.39 | 12652.75 | 11982.9 | 7.2 | 13.5 | 9.87 | 31.88 | 31.27 | 31.06 | 28.68 | 29.32 | 29.64 | 28.51 | 25.33 | 2 | 8.7 | Dec 2025 | 16.86 | 20.21 | 0.07 | 30.79 | 37.7 | -0.43 | 0.6 | 0 | 1.68 | 30.58 | 31.97 | Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India. **Website:** [https://www.sunpharma.com](https://www.sunpharma.com) | 54.48 | 8.57 | 16.12 | 20.72 | 54.48 | 16.55 | 20.12 | 5.29 | 405187.91 | 20.65 | 7.13 | |||||||
| 26 | 75 | 87 | 74 | 16/02/2024 | Pharmaceuticals | 5138 | 1.7 | -5.5 | 14.7 | 0.5 | 4.7 | 4.8 | 21.8 | 25.1 | DAILY | 1180.9 | 1132.42 | 1104.8 | 1115.36 | 1139.51 | 1141.34 | 1126.69 | 1158.15 | 1160.35 | 1187.22 | 11.1 | False | False | 2.07 | NA | False | False | False | 94.5 | Healthcare | 47.6 | False | False | False | False | False | False | 2.8 | False | 20 | 0.34 | 11.4 | 11 | 15.3 | True | 96476.6 | 93054.36 | 120037.42 | 104485.86 | 90817.94 | False | 32 | 70.6 | 76.81 | 79.39 | 13.8 | 4.3 | 4.8 | 4.4 | 4.3 | 39.2 | 39.2 | 25.5 | NA | 0.5 | False,False;False,False;False,False | [False, True, False] | ['2025-05-26', 1510.8, '2025-12-29', 944.0] | 1249.1 | Dec 2025:12/02/2026,Sep 2025:12/11/2025,Jun 2025:08/08/2025 | Entero Healthcare Solutions Limited | 2.1 | 10.4 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e6f1137-7f92-40eb-8992-b849450fbedc.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=78bba0a0-8086-4fae-bbf4-fcc270f57e62.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/42b7ec8f-1c9a-4492-bc0d-5dd189b631cc.pdf | 7.7 | 9.1 | 10.3 | 22.7 | ['DAILY', '2026-04-09', '2026-04-08'] | 33.88 | 36.6 | 30.23 | 31.43 | 29.45 | 26.04 | 20.53 | 21.18 | -7.4 | 15 | 6.35 | 7.26 | 6.39 | 5.91 | 5.85 | 5.43 | 4.62 | 4.82 | -12.5 | 8.5 | 21.8 | 8.99 | 1706.52 | 1570.95 | 1403.82 | 1339.06 | 1359 | 1300.69 | 1097.04 | 1034.18 | 8.6 | 25.6 | 30.44 | 3.97 | 3.95 | 3.57 | 3.65 | 3.68 | 3.26 | 2.75 | 2.79 | 0.5 | 7.9 | Dec 2025 | 5.63 | 8.71 | 0.25 | 3.8 | 45.6 | -9.54 | 6.78 | 0 | 0.61 | 46.49 | 55.91 | Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products to retail pharmacies, hospitals, healthcare product manufacturers, and healthcare clinics in India. The company is involved in the distribution of medical devices, over the counter medical products, nutraceuticals, and vaccines. It also offers nebulizers, digital thermometers, blood pressure monitors, and adult diapers. Entero Healthcare Solutions Limited was incorporated in 2018 and is based in Mumbai, India. **Website:** [https://www.enterohealthcare.com](https://www.enterohealthcare.com) | 52.42 | 26.03 | 5.14 | 16.42 | 52.42 | 14.68 | 9.64 | 2.91 | 5476.97 | 21.79 | 0.91 | |||||||
| 27 | 74 | 19 | 50 | 01/01/1996 | Pharmaceuticals | 36784 | 0.3 | -2.6 | -3.5 | -7.9 | 8.2 | 12 | 10.7 | 15.8 | DAILY | 1449.9 | 1420.75 | 1421.66 | 1492.37 | 1525.5 | 1442.53 | 1496.13 | 1505.28 | 1504.85 | 1488.79 | 44.2 | False | False | 14.02 | Nifty Pharma,Nifty Healthcare,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | 95.2 | Healthcare | 55.3 | False | False | False | False | False | False | 1.5 | False | 20 | 0.29 | 29.9 | 22.9 | 28.6 | True | 287174.5 | 220804.46 | 258083.57 | 245562.69 | 262657.91 | False | 42 | 76.57 | 77.75 | 77.55 | 8.6 | 3.5 | 4 | 3.7 | 3.5 | 66.4 | 66.4 | 17.4 | NA | -0.1 | True,False;True,False;False,False | [False, False, False] | ['2026-03-17', 1624.0, '2025-10-24', 1251.6] | 1601.2 | Dec 2025:13/02/2026,Sep 2025:13/11/2025,Jun 2025:11/08/2025 | IPCA Laboratories Limited | -2.4 | 9.3 | Jun 2025:NA | 4.2 | 6.3 | 12.7 | 12.9 | ['DAILY', '2026-04-09', '2026-04-08', '2026-04-07'] | 363.67 | 280.53 | 232.89 | 63.99 | 276.36 | 245.75 | 199.14 | 1.33 | 29.6 | 31.6 | 12.86 | 11.14 | 9.19 | 2.67 | 9.78 | 9.05 | 7.58 | 2.35 | 15.4 | 31.5 | 29.08 | 21.57 | 2392.5 | 2556.5 | 2308.85 | 2246.69 | 2245.37 | 2354.9 | 2092.63 | 2033.03 | -6.4 | 6.6 | 14.01 | 22.29 | 21.32 | 18.04 | 19.09 | 20.62 | 18.75 | 18.77 | 15.83 | 4.5 | 8.1 | Dec 2025 | 12.75 | 14.72 | 0.17 | 20.24 | 40.4 | 0.01 | 0.14 | 0 | -23.53 | 28.19 | 37.98 | Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India. **Website:** [https://www.ipca.com](https://www.ipca.com) | 44.72 | 7.21 | 10.63 | 37.13 | 44.72 | 10.62 | 36.99 | 4.95 | 37784.43 | 18.61 | 3.98 | |||||||
| 28 | 74 | 77 | 89 | 28/11/2025 | Pharmaceuticals | 6927 | -0.4 | -0.3 | 9.9 | 12.2 | -20.8 | -20.8 | 22.9 | 17 | DAILY | 613.3 | NA | NA | 619.34 | 608.07 | NA | 618.83 | 610.59 | 610.43 | 609.85 | 7.7 | False | False | 2.69 | NA | False | False | False | NA | Healthcare | 23.8 | False | False | False | False | False | False | 2.1 | False | 10 | 0.3 | 9.1 | 7.4 | NA | True | 126158.55 | 101752.08 | NA | 1338302.47 | 135929.59 | False | NA | 43.41 | 50.47 | 59.17 | 0 | 3.6 | 3.9 | 4.6 | 4.6 | 12.8 | 12.8 | 22.9 | NA | -0.2 | False,False;False,False;False,False | [False, False, False] | ['2025-11-28', 795.0, '2026-01-21', 524.0] | 675.6 | Dec 2025:06/02/2026,Sep 2025:19/12/2025 | Sudeep Pharma Limited | -4 | 7.7 | Jun 2025:NA,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8e62e087-62c8-4fa5-a09e-1f9b488bd0fd.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/ddd9338d-355f-4f2f-9c70-3d3d0095a3f5.pdf | 9.4 | 9.7 | 11.7 | 15.3 | ['DAILY', '2026-04-09', '2026-04-08'] | 47.7 | 46.78 | 31.27 | NA | 28.71 | 48.75 | NA | NA | 2 | 66.1 | 4.2 | 4.71 | 3.17 | NA | 2.95 | 128.13 | NA | NA | -10.8 | 42.4 | 14.27 | 945.36 | 172.34 | 162.67 | 124.92 | NA | 115.54 | 148.8 | NA | NA | 5.9 | 49.2 | 32.48 | 34.8 | 34.09 | 35.12 | NA | 34.01 | 42.66 | NA | NA | 2.1 | 2.3 | Dec 2025 | 32.77 | 35.65 | 0.2 | 38.06 | 43 | 0 | 0 | 0 | 1.09 | 36.51 | 43.1 | NA | 76.15 | 4.57 | 1.67 | 17.59 | 76.15 | 1.67 | 17.59 | 9.56 | 7005.19 | 34.96 | 13.95 | |||||||
| 29 | 71 | 12 | 28 | 03/09/2025 | Pharmaceuticals | 646 | 1.9 | 7.5 | -5.6 | -14.6 | -6.8 | 32.6 | 29.6 | 34 | DAILY | 121.61 | NA | NA | 118.77 | 117.07 | NA | 120.35 | 116.86 | 116.8 | 116.96 | 2.7 | False | False | 2.52 | NA | False | False | False | NA | Healthcare | 47.3 | False | False | False | False | False | False | 4.2 | False | 20 | 0.77 | 2.7 | 3.2 | 2.5 | False | 223271.1 | 256169.6 | NA | 278886.54 | 234973.92 | False | NA | 82.62 | 74.91 | 72.89 | 21.7 | 3.8 | 4.4 | 4.5 | 5.4 | 50.4 | 50.4 | 29.6 | NA | 1.3 | False,False;False,False;False,False | [False, False, False] | ['2025-11-28', 172.8, '2025-09-03', 90.8] | 128.86 | Dec 2025:09/02/2026,Sep 2025:11/11/2025 | Anlon Healthcare Limited | -3.4 | 5.7 | Jun 2025:NA,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6cd8d26e-593d-4098-a1ba-c8f614de2aec.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachHis/e0daa815-7030-4787-b4aa-9eeb35fefda0.pdf | 6.3 | 9.9 | 9.9 | 16.4 | 5.15 | 9.32 | 3.55 | NA | -2.49 | 2.59 | NA | NA | -44.7 | 306.8 | 0.97 | 1.75 | 0.89 | 2.84 | -0.62 | 0.65 | NA | NA | -44.6 | 256.5 | 5.15 | 6.04 | 35.58 | 52.2 | 33.3 | NA | 9.36 | 24.17 | NA | NA | -31.8 | 280.1 | NA | 34.71 | 26.32 | 18.74 | NA | 6.2 | 31.11 | NA | NA | 31.9 | 459.8 | Dec 2025 | 40.45 | 24.83 | 0.27 | 27.06 | 23.6 | 0.23 | 1.66 | 0 | 0.05 | 31.34 | 24.67 | NA | 52.68 | 42.6 | 0.23 | 4.49 | 52.68 | 0 | 2.83 | 3.02 | 680.62 | 20.8 | 5.66 | ||||||||
| 31 | 70 | 29 | 74 | 01/07/2002 | Pharmaceuticals | 90787 | 1.2 | 4.4 | -0.7 | 0.8 | -9.3 | 6.9 | 14.8 | 11 | DAILY | 902.25 | 947.7 | 938.42 | 898.25 | 889.51 | 928.63 | 897.44 | 888.38 | 887.96 | 883.98 | 59 | False | False | 25.16 | Nifty Pharma,Nifty Healthcare,Nifty Manufacturing,Nifty 100,Nifty 500 | False | False | False | 78.4 | Healthcare | 25 | False | False | False | False | False | False | 2.3 | True | No Band | 1.06 | 37.3 | 38.8 | 39.8 | False | 664537.5 | 693721.18 | 853627.42 | 693344.49 | 701532.6 | False | 47 | 66.86 | 67.72 | 68.15 | 2.8 | 2.5 | 2.7 | 2.6 | 2.4 | 16 | 16 | 31.9 | NA | 0 | False,False;False,False;False,False | [True, False, False] | ['2025-09-19', 1059.1, '2025-04-16', 813.0] | 938.5 | Dec 2025:09/02/2026,Sep 2025:06/11/2025,Jun 2025:12/08/2025 | Zydus Lifesciences Limited | -2.3 | 2.6 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dde79516-6d2a-4c21-8cbf-5b4ca26d5757.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68e6336b-5e24-4d76-95fa-eff0c21897c7.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/92fec597-5665-48a4-b102-1872064c91e8.pdf | 6.1 | 8.2 | 8.2 | 10.8 | [906.1, '18/03/2026', 'DAILY'] | 1022.9 | 1238.6 | 1521 | 1243.7 | 1026.2 | 920.2 | 1482.5 | 1246.1 | -17.4 | -0.3 | 10.36 | 12.51 | 14.58 | 11.64 | 10.17 | 9.06 | 14.11 | 11.75 | -17.2 | 1.9 | 44.97 | 38.36 | 6864.5 | 6123.2 | 6573.7 | 6527.9 | 5269.1 | 5237 | 6207.5 | 5533.8 | 12.1 | 30.3 | 10.27 | 26.46 | 32.92 | 31.77 | 32.56 | 26.33 | 27.91 | 33.57 | 29.46 | -19.6 | 0.5 | Dec 2025 | 21.21 | 24.31 | 0.38 | 30.84 | 18.4 | -0.28 | 0.22 | 0.01 | 8.63 | 21.77 | 21.82 | Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust. **Website:** [https://zyduslife.com](https://zyduslife.com) | 75 | 6.86 | 7.06 | 11.08 | 74.99 | 7.34 | 10.86 | 3.59 | 97641.06 | 11.48 | 3.74 | |||||||
| 32 | 68 | 71 | 66 | 01/07/2002 | Pharmaceuticals | 22256 | 1.5 | 7.7 | 7.9 | -2.4 | -2.1 | 14.1 | 26.7 | 26 | DAILY | 1369.7 | 1437.11 | 1371.12 | 1314.75 | 1236.92 | 1361.76 | 1299.43 | 1267.39 | 1266.85 | 1279.84 | 90.1 | True | False | 8.27 | Nifty Pharma,Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 70.4 | Healthcare | 50.9 | False | False | False | False | True | 25/03/2026 | True | 5 | False | 20 | 1.02 | 39 | 29.3 | 49.9 | False | 736311.9 | 557435.78 | 801782.07 | 691320.72 | 731137.79 | False | 20.9 | 73.82 | 67.01 | 64.63 | 24.2 | 4 | 4.7 | 4.5 | 4 | 27.2 | 27.2 | 31.5 | NA | -0.5 | False,False;False,False;False,False | [True, False, False] | ['2025-06-12', 1868.8, '2026-03-23', 1086.7] | 1433.4 | Dec 2025:10/02/2026,Sep 2025:03/11/2025,Jun 2025:08/08/2025 | Wockhardt Limited | -4.2 | 1.8 | Jun 2025:NA | 10.8 | 13.2 | 17.4 | 22.7 | 61 | 82 | -108 | -45 | 20 | -16 | -16 | -177 | -25.6 | 205 | 3.63 | 4.8 | -5.54 | -1.54 | 0.86 | -1.43 | -0.91 | -11.02 | -24.4 | 322.1 | -2.89 | -30.18 | 888 | 782 | 738 | 743 | 721 | 809 | 739 | 700 | 13.6 | 23.2 | 1.15 | 19.93 | 22.76 | 9.76 | 8.61 | 17.75 | 13.6 | 12.31 | -8.43 | -12.4 | 12.3 | Dec 2025 | -1.22 | 3.75 | 0.54 | 15.58 | 1014.6 | -0.1 | -0.45 | 0 | 13.82 | 94.33 | 393.67 | Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram negative infections; and WCK 4873, which is phase 3 clinical trial for community-acquired bacterial pneumonia. It also offers rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company develops and commercializes Biovac-B, a hepatitis B vaccine; WEPOX, a recombinant human erythropoietin; WOSULIN, a recombinant human insulin; and GLARITUS, a recombinant insulin glargine. Further, it provides contract manufacturing services; offers and active pharmaceutical ingredients. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India. **Website:** [https://www.wockhardt.com](https://www.wockhardt.com) | 49.08 | 33.36 | 7 | 10.55 | 49.08 | 7.1 | 11 | 4.87 | 24504.96 | 42.84 | 7.78 | |||||||
| 33 | 64 | 75 | 83 | 16/08/2021 | Pharmaceuticals | 1686 | 1.5 | 4.5 | 9.3 | 6.3 | -12.9 | -10.4 | 29.9 | 14.6 | DAILY | 799.2 | 863.9 | 835.94 | 777.75 | 750.04 | 834.95 | 771.53 | 762.49 | 762.62 | 770.41 | 2.8 | True | False | 0.8 | NA | False | False | False | 64.8 | Healthcare | 38 | False | False | False | False | False | False | 5.3 | False | 20 | 0.94 | 2 | 1.9 | 2.1 | False | 37681.7 | 36246.2 | 48317 | 37120.84 | 37171.77 | False | 47.6 | 58.56 | 58.6 | 60.8 | 15.8 | 3.8 | 3.8 | 3.8 | 3.8 | 16.8 | 16.8 | 33.3 | NA | 0.8 | False,False;False,False;False,False | [False, False, False] | ['2025-04-17', 1140.0, '2026-03-16', 697.4] | 871.4 | Dec 2025:05/02/2026,Sep 2025:06/11/2025,Jun 2025:12/08/2025 | Windlas Biotech Limited | -4.5 | 7.2 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a0de84a-237b-4675-8de3-3480ea84f5e9.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6103d9a2-a794-4438-9a50-a1b02bb3bc10.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/87bf83d0-65ff-42f0-b86b-cb804a354e88.pdf | 6.9 | 8.2 | 10.9 | 14.3 | [806.6, '16/02/2026', 'DAILY'] | 15 | 17.8 | 17.66 | 16.28 | 15.58 | 15.66 | 13.48 | 16.99 | -15.7 | -3.7 | 7.12 | 8.45 | 8.43 | 7.77 | 7.45 | 7.49 | 6.45 | 8.17 | -15.7 | -4.4 | 29.1 | 27.98 | 233.1 | 222.4 | 210.09 | 202.71 | 195.02 | 187 | 175.15 | 171.29 | 4.8 | 19.5 | 18.24 | 10.46 | 12.84 | 12.63 | 12.6 | 12.63 | 12.33 | 11.92 | 12.85 | -18.5 | -17.2 | Dec 2025 | 12.76 | 16.96 | 0.06 | 12.09 | 25.2 | -0.18 | 0 | 0 | 1.48 | 28.06 | 19.1 | Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO solutions, including product development, licensing, and commercial manufacturing of complex drugs and dosage forms. It also produces nutraceutical supplement products. In addition, the company manufactures tablets, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprising fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, chewable or dispersible, and plain oral solids. Windlas Biotech Limited was incorporated in 2001 and is based in Gurugram, India. **Website:** [https://windlas.com](https://windlas.com) | 61.99 | 25.64 | 0.93 | 11.44 | 61.99 | 1.11 | 11.44 | 3.15 | 1700.1 | 13.77 | 1.96 | |||||||
| 34 | 62 | 12 | 42 | 12/03/2003 | Pharmaceuticals | 158020 | 1.2 | 1.6 | -6 | -10 | -2.9 | 10.5 | 15.8 | 13.8 | DAILY | 5952.5 | 6329.92 | 6271.11 | 6145.93 | 6035.73 | 6199.88 | 6132.89 | 6019.28 | 6012.9 | 5934.96 | 180 | False | False | 12.77 | Nifty Pharma,Nifty Healthcare,Nifty Manufacturing,Nifty 100,Nifty 500 | False | False | False | 80.9 | Healthcare | 48.1 | False | False | False | False | False | False | 1.9 | True | No Band | 0.79 | 118.1 | 133.5 | 125.9 | False | 299616.6 | 339554.96 | 379952.87 | 333042.69 | 330669.42 | False | 30.2 | 71.81 | 67.44 | 66.8 | 26.2 | 2.8 | 2.5 | 2.5 | 2.3 | 51.2 | 51.2 | 15.8 | NA | -0.5 | False,False;False,False;False,False | [False, False, False] | ['2025-07-08', 7071.5, '2025-04-09', 5231.6] | 6474 | Dec 2025:11/02/2026,Sep 2025:07/11/2025,Jun 2025:06/08/2025 | Divi's Laboratories Limited | -6.8 | 6.4 | Jun 2025:NA | 4.6 | 5.6 | 7.8 | 12.8 | ['WEEKLY', '2026-04-06', '2026-03-30'] | 583 | 689 | 545 | 662 | 589 | 510 | 430 | 538 | -15.4 | -1 | 21.96 | 25.95 | 20.53 | 24.94 | 22.19 | 19.21 | 16.2 | 20.27 | -15.4 | -1 | 82.53 | 60.27 | 2604 | 2715 | 2410 | 2585 | 2319 | 2338 | 2118 | 2303 | -4.1 | 12.3 | 11.65 | 34.18 | 32.71 | 30.25 | 34.27 | 32.04 | 30.62 | 29.37 | 31.74 | 4.5 | 6.7 | Dec 2025 | 15.35 | 20.44 | 0.01 | 32.9 | 63.7 | 0.69 | -0.5 | -0.01 | -6.52 | 67.77 | 65.95 | Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India. **Website:** [https://www.divislabs.com](https://www.divislabs.com) | 51.88 | 8.75 | 20.08 | 19.18 | 51.89 | 19.39 | 19.68 | 10.25 | 154869.32 | 40.43 | 15.02 | |||||||
| 35 | 59 | 32 | 76 | 15/04/2005 | Pharmaceuticals | 782 | 2.6 | 5.7 | -0.1 | 1.8 | -5.2 | -6.9 | 54 | 16.5 | DAILY | 78.04 | 84.39 | 79.78 | 76.25 | 74.29 | 82.88 | 75.78 | 74.45 | 74.4 | 74.23 | 0.4 | False | False | 2.82 | NA | False | False | False | 64.9 | Healthcare | 28.2 | False | False | False | False | True | 30/03/2026 | False | 3.7 | False | 20 | 0.85 | 0.5 | 0.5 | 0.4 | False | 54311.85 | 50463.5 | 69139.02 | 50570.03 | 52757.25 | False | 57.7 | 52.78 | 57.99 | 59.38 | 7.8 | 3.6 | 4.6 | 4.4 | 4.1 | 20.8 | 20.8 | 54 | NA | -0.5 | False,False;False,False;False,False | [True, False, False] | ['2025-05-02', 169.6, '2026-03-30', 67.0] | 83.98 | Dec 2025:06/02/2026,Sep 2025:07/11/2025,Jun 2025:08/08/2025 | Anuh Pharma Limited | -1.6 | 7.2 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0fa3838-c22a-4161-a752-fd07d6dfeea1.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9cd8b518-8788-471a-9560-fd08aa047c87.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/db22e9a2-e45f-47cc-8e49-a8896830b1b5.pdf | 8.1 | 9.9 | 14.7 | 16.2 | [78.3, '26/02/2026', 'DAILY'] | 13.45 | 7.61 | 8.3 | 12.46 | 10.34 | 15.04 | 9.51 | 15.36 | 76.7 | 30.1 | 1.34 | 0.76 | 0.83 | 1.24 | 1.03 | 1.5 | 0.95 | 1.53 | 76.3 | 30.1 | 4.73 | 5.99 | 197.18 | 185.88 | 186.48 | 198.14 | 159.51 | 165.95 | 137.91 | 163.89 | 6.1 | 23.6 | 16.6 | 8.52 | 6.39 | 5.52 | 9.42 | 9.27 | 10.17 | 7.66 | 11.73 | 33.3 | -8.1 | Dec 2025 | 13.41 | 17.24 | 0 | 7.51 | 18.7 | 0 | 0 | 0 | 1.43 | 14.56 | 18.51 | Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and intermediates. The company also provides corticosteroids, such as anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, and anti-histamines. It also exports its products. The company was incorporated in 1960 and is headquartered in Mumbai, India. **Website:** [https://www.anuhpharma.com](https://www.anuhpharma.com) | 71.82 | 28.17 | 0 | 0 | 71.82 | 0 | 0 | 2.39 | 783.94 | 11.61 | 1.02 | ||||||
| 36 | 58 | 82 | 71 | 14/06/2016 | Pharmaceuticals | 414 | 8.2 | 10.9 | 11.9 | -0.7 | -8.3 | -6.4 | 24.2 | 25.2 | DAILY | 725.8 | 779.05 | 751.14 | 686.13 | 660.05 | 780.21 | 685.11 | 665.26 | 664.69 | 664.37 | 0.7 | True | False | 0.22 | NA | False | True | False | 148.8 | Healthcare | 37.8 | False | False | True | 09/04/2026 | True | True | 09/04/2026 | True | 13.4 | False | 20 | 5.36 | 0.8 | 0.4 | 0.3 | False | 10955.4 | 6399.22 | 5890.87 | 8134.63 | 12453.42 | False | 55.4 | 43.62 | 53.95 | 57.46 | 4.9 | 6.2 | 4.8 | 4.6 | 4.1 | 14.4 | 14.4 | 58.6 | NA | 0.6 | False,False;False,False;False,False | [True, False, False] | ['2025-07-07', 957.5, '2026-03-30', 579.9] | 750.2 | Dec 2025:11/02/2026,Sep 2025:12/11/2025,Jun 2025:02/08/2025 | Albert David Limited | 1.2 | 8.7 | Jun 2025:NA | 15 | 21.8 | 24.7 | 24.7 | [747.8, '18/02/2026', 'DAILY'] | 15.3 | -3.3 | 7.94 | -10.33 | -9.39 | 18.07 | 18.84 | 12.91 | 563.6 | 262.9 | 26.81 | -5.78 | 13.91 | -18.1 | -16.45 | 31.66 | 33.01 | 22.62 | 563.8 | 263 | 30.14 | 132.15 | 89.93 | 87.24 | 70.57 | 74.89 | 83.08 | 98.44 | 89.36 | 89.06 | 3.1 | 8.2 | 1.52 | 12.04 | 2.91 | -15.11 | -6.34 | 0.82 | 6.32 | 0.98 | 10.75 | 313.7 | 1368.3 | Dec 2025 | 4.39 | 6.45 | 0.11 | -0.63 | 43.1 | 0 | 0 | 0 | -2.14 | 6.77 | 10.28 | Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India. It offers formulations for parenterals, oral/enteral, topical agents, and vision care products. The company exports its products to Latin American, Southeast Asian, and other African countries. Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India. **Website:** [https://www.albertdavidindia.com](https://www.albertdavidindia.com) | 62.24 | 35.51 | 0.6 | 1.65 | 62.24 | 0.6 | 1.65 | 1.05 | 431.77 | 17.17 | 1.34 | |||||
| 37 | 54 | 71 | 56 | 19/10/2004 | Pharmaceuticals | 3008 | 0.2 | 4 | 8.1 | -6 | -18 | -3.2 | 26.4 | 11.9 | DAILY | 300 | 337.4 | 327.74 | 292.95 | 289.15 | 329.33 | 296.09 | 289.77 | 289.75 | 291.23 | 1.7 | False | False | 2.76 | NA | False | False | False | 89.9 | Healthcare | 27.5 | False | False | False | False | True | 17/03/2026 | True | 4.1 | False | 20 | 0.83 | 1.2 | 1 | 1.1 | False | 57328.9 | 46496.96 | 56382.9 | 48720.9 | 49446.78 | False | 45.9 | 46.49 | 46.46 | 48.88 | 1.8 | 4.5 | 4.8 | 4.7 | 4.4 | 20 | 20 | 40.5 | NA | -0.8 | False,False;False,False;False,False | [False, False, False] | ['2025-07-30', 407.9, '2026-03-09', 268.0] | 309.5 | Dec 2025:13/02/2026,Sep 2025:14/11/2025,Jun 2025:13/08/2025 | Gufic Biosciences Limited | -3.1 | 1.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14134779-988a-41c8-89a1-382acc0ee34f.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2029e06-73d2-4994-b812-c2bea38f695b.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/daf62c52-7d69-48b9-99b1-0bc3e304de11.pdf | 7.8 | 9.6 | 11.7 | 11.7 | [304.1, '11/03/2026', 'DAILY'] | ['DAILY', '2026-04-09', '2026-04-08'] | 12.42 | 16.82 | 13.07 | 7.72 | 19.31 | 21.78 | 20.86 | 20.05 | -26.2 | -35.7 | 1.24 | 1.68 | 1.2 | 0.79 | 1.93 | 2.17 | 2.08 | 2 | -26.2 | -35.8 | 6.95 | 8.59 | 231.41 | 237.05 | 223.72 | 205.02 | 207.79 | 204.18 | 202.81 | 194.99 | -2.4 | 11.4 | NA | 14.25 | 15.96 | 14.88 | 12.87 | 16.33 | 18.92 | 17.64 | 17.55 | -10.7 | -12.7 | Dec 2025 | 12.27 | 13.15 | 0.58 | 14.54 | 60.1 | 0.11 | 0.08 | 0 | NA | 60.48 | 51.9 | Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. The company was founded in 1970 and is based in Mumbai, India. **Website:** [https://www.gufic.com](https://www.gufic.com) | 72.5 | 23.3 | 0.44 | 3.74 | 72.5 | 0.33 | 3.66 | 4.77 | 3277.6 | 24.33 | 3.65 | |||||
| 38 | 54 | 62 | 81 | 25/11/2022 | Pharmaceuticals | 382 | 0.7 | 6 | 6 | 4.8 | -0.9 | -16.9 | 43.7 | 20.5 | DAILY | 71.49 | 78.53 | 71.42 | 69.33 | 66.28 | 76.78 | 68.61 | 67.3 | 67.28 | 67.77 | 0.6 | False | False | 3.73 | NA | False | False | False | 60.9 | Healthcare | 69.7 | False | False | False | False | True | 17/03/2026 | True | 3.3 | False | 20 | 0.55 | 1 | 0.8 | 0.7 | True | 87493.95 | 71928.72 | 116892.35 | 79451.78 | 75592.85 | False | 41.3 | 45.5 | 53.99 | 55.54 | 8.5 | 5.4 | 6.3 | 6.3 | 5.8 | 17.6 | 17.6 | 53.2 | NA | 0.3 | False,False;False,False;False,False | [True, False, False] | ['2025-07-18', 127.0, '2026-03-30', 59.3] | 76.52 | Dec 2025:11/02/2026,Sep 2025:12/11/2025,Jun 2025:07/08/2025 | Zim Laboratories Limited | -6.6 | 4.3 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f794103f-f48f-4ea5-8e1b-f5a940a507b8.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e31fe51-1bf2-470c-bcec-aa53fd8d325c.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/b3d21ea6-3445-47b4-8cc5-6c790dbe58ea.pdf | 7.4 | 14.4 | 18.2 | 19.9 | [72.2, '18/02/2026', 'DAILY'][72.0, '23/02/2026', 'WEEKLY'] | ['DAILY', '2026-04-09', '2026-04-08'] | 4.4 | -0.42 | -1.87 | 4.88 | 4 | 2.38 | 0.9 | 8.09 | 1147.6 | 10 | 0.9 | -0.09 | -0.38 | 1 | 0.82 | 0.49 | 0.18 | 1.66 | 1100 | 9.8 | 2.5 | 3.54 | 108.66 | 88.71 | 71.76 | 108.73 | 96.33 | 92.14 | 81.82 | 117.86 | 22.5 | 12.8 | 6.42 | 11.79 | 6.49 | 5.92 | 13.43 | 12 | 10.34 | 9.83 | 13.28 | 81.7 | -1.8 | Dec 2025 | 4.96 | 8.16 | 0.48 | 9.9 | 50 | 0 | -0.17 | -2.96 | -9.42 | 19.86 | 29.86 | ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India. **Website:** [https://www.zimlab.in](https://www.zimlab.in) | 30.3 | 69.64 | 0 | 0.07 | 33.26 | 0 | 0.24 | 1.39 | 500.79 | 11.29 | 1.33 | |||||
| 39 | 50 | 32 | 40 | 30/01/2023 | Pharmaceuticals | 6173 | -1.1 | 5.5 | 0 | -10.6 | -18.4 | 9.1 | 29.9 | 16.4 | DAILY | 680.95 | 793.13 | 762.87 | 698.24 | 647.42 | 745.66 | 686.19 | 657.76 | 656.85 | 653.97 | 13.9 | False | False | 5.16 | NA | False | False | False | 67.7 | Healthcare | 56.9 | False | False | False | False | False | False | 3.2 | False | 20 | 0.54 | 13.6 | 12.2 | 13.5 | False | 217306.75 | 194509.34 | 271256.69 | 209287 | 211435.17 | False | 53.7 | 60.09 | 50.82 | 49.06 | 39.8 | 4.2 | 4.3 | 4.1 | 3.8 | 16 | 16 | 29.9 | NA | 1.3 | False,False;False,False;False,False | [True, False, False] | ['2025-07-16', 971.0, '2026-03-30', 585.0] | 794.75 | Dec 2025:09/02/2026,Sep 2025:09/11/2025,Jun 2025:12/08/2025 | Aarti Pharmalabs Limited | -14.3 | 0.6 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4a5587f-7ee8-4fb7-8ee5-07d93610c2a8.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46d58674-e6a3-408b-8347-9ef5132efe9b.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/c371bec7-ba30-43fc-831f-cf12647c167a.pdf | 8 | 11.8 | 16.1 | 16.4 | 47.96 | 27.92 | 49.5 | 88.34 | 73.99 | 54.62 | 55.45 | 65.25 | 71.8 | -35.2 | 5.29 | 3.08 | 5.46 | 9.75 | 8.16 | 6.03 | 6.12 | 7.2 | 71.8 | -35.2 | 30.05 | 23.93 | 432.27 | 418.33 | 386.19 | 563.78 | 537.78 | 458.03 | 555.49 | 505.77 | 3.3 | -19.6 | NA | 23.67 | 17.71 | 24.2 | 25.83 | 23.91 | 20.45 | 17.36 | 23.24 | 33.7 | -1 | Dec 2025 | 14.54 | 17.44 | 0.32 | 23.07 | 28.9 | -0.33 | 0.71 | 0.22 | 0.94 | 32.18 | 25.62 | Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acidic and allied products comprising sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India. **Website:** [https://www.aartipharmalabs.com](https://www.aartipharmalabs.com) | 43.1 | 41.54 | 7.69 | 7.66 | 42.88 | 8.02 | 6.95 | 3.02 | 6789.14 | 16.16 | 3.77 | ||||||||
| 40 | 50 | 30 | 48 | 23/06/2014 | Pharmaceuticals | 12633 | 0.1 | 6.1 | -0.5 | -8.4 | -18 | -3 | 30.6 | 10.8 | DAILY | 1662 | 1935.06 | 1888.44 | 1691.63 | 1615.62 | 1858.07 | 1683.45 | 1622.58 | 1620.69 | 1610.16 | 13.2 | False | False | 2.24 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 81.1 | Healthcare | 29.4 | False | False | False | False | False | False | 2.7 | False | 20 | 0.83 | 8 | 7.3 | 6.7 | False | 82208.2 | 75118.26 | 90214.33 | 78569.36 | 89026.5 | False | 55.3 | 48.71 | 42.46 | 43.27 | 28.6 | 3.5 | 3.1 | 2.8 | 2.6 | 4 | 4 | 37.1 | NA | 0.1 | False,False;False,False;False,False | [True, False, False] | ['2025-09-17', 2395.0, '2026-03-30', 1500.3] | 1903.9 | Dec 2025:05/02/2026,Sep 2025:05/11/2025,Jun 2025:07/08/2025 | Caplin Point Laboratories Limited | -12.7 | 1.8 | Jun 2025:https://www.caplinpoint.net/wp-content/uploads/2025/08/Q1FY26-PPT-final.pdf,Sep 2025:https://www.caplinpoint.net/wp-content/uploads/2025/08/Earnings-Call-Presentation-Q2-FY26.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/f761aa80-9ccc-4e05-9554-153ba6062c17.pdf | 8.5 | 10.8 | 11.2 | 12.3 | 165.86 | 160.23 | 150.76 | 145.28 | 140.07 | 130.81 | 124.92 | 121.23 | 3.5 | 18.4 | 21.56 | 20.32 | 20.1 | 18.76 | 18.28 | 17.21 | 16.31 | 16.01 | 6.1 | 17.9 | 70.56 | 60.19 | 542.77 | 534.04 | 510.22 | 502.45 | 492.96 | 483.1 | 458.96 | 453.22 | 1.6 | 10.1 | 17.55 | 34.94 | 35.42 | 34.84 | 33.45 | 32.92 | 34.08 | 33.08 | 32.04 | -1.4 | 6.1 | Dec 2025 | 22.66 | 25.85 | 0 | 34.68 | 20.6 | 0.07 | -0.05 | 0 | 0.96 | 19.27 | 22.23 | Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India. **Website:** [https://www.caplinpoint.net](https://www.caplinpoint.net) | 70.57 | 20.81 | 6.58 | 2.05 | 70.57 | 6.51 | 2.1 | 4 | 11991.74 | 14.31 | 5.74 | ||||||||
| 41 | 48 | 14 | 54 | 09/05/2023 | Pharmaceuticals | 84803 | 0.6 | 2.8 | -5 | -6.7 | -17.1 | -11.2 | 24.4 | 7.6 | DAILY | 2054.2 | 2316.29 | 2255.53 | 2093.99 | 2061.63 | 2251.85 | 2097.7 | 2055.44 | 2053.52 | 2034.07 | 125.5 | False | False | 11.29 | Nifty Pharma,Nifty Healthcare,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | 116.3 | Healthcare | 27.3 | False | False | False | False | False | False | 2.5 | True | No Band | 0.38 | 130.3 | 115.6 | 104.1 | False | 610903.7 | 542081.44 | 530527.1 | 555043.62 | 577028.02 | False | 41.9 | 51.77 | 51.2 | 51.56 | 20 | 3.1 | 3.3 | 3.1 | 3.1 | 10.4 | 10.4 | 32.8 | NA | -0.1 | False,False;False,False;False,False | [False, False, False] | ['2025-07-15', 2716.5, '2026-03-23', 1909.7] | 2279.7 | Dec 2025:03/02/2026,Sep 2025:06/11/2025,Jun 2025:31/07/2025 | Mankind Pharma Limited | -5 | 5.7 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9390a370-5720-4b96-8d2c-d1065a2ab458.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7951849a-2f16-43f2-a94b-a1740f7d2ca1.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/fa7f58c8-bb30-43c8-8184-df124142ee0b.pdf | 5.8 | 8.6 | 8.6 | 15.4 | 413.88 | 520.18 | 444.62 | 424.65 | 385 | 659 | 543 | 477 | -20.4 | 7.5 | 9.9 | 12.39 | 10.62 | 10.2 | 9.22 | 16.31 | 13.39 | 11.76 | -20.1 | 7.4 | 48.26 | 47.75 | 3567.2 | 3697.16 | 3570.35 | 3079.37 | 3230 | 3077 | 2893 | 2441 | -3.5 | 10.4 | 15.79 | 25.77 | 24.92 | 23.72 | 22.19 | 26 | 28 | 24 | 24 | 3.4 | -0.9 | Dec 2025 | 14.68 | 15.98 | 0.55 | 24.23 | 47.7 | -1.49 | 1.35 | -0.01 | 5.52 | 51.87 | 50.23 | Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India. **Website:** [https://www.mankindpharma.com](https://www.mankindpharma.com) | 72.66 | 2.75 | 11.34 | 13.26 | 72.67 | 12.83 | 11.91 | 5.55 | 92600.11 | 23.88 | 6.66 | ||||||||
| 42 | 48 | 72 | 28 | 28/12/2021 | Pharmaceuticals | 5058 | -1.3 | 2.7 | 8.2 | -14.7 | -12.7 | -5.9 | 24.5 | 15.2 | DAILY | 628.55 | 696.55 | 700.69 | 636.69 | 591.52 | 678.13 | 634.93 | 607.45 | 606.85 | 608.55 | 9.6 | False | False | 2.55 | NA | False | False | False | 71.3 | Healthcare | 31.7 | False | False | False | False | False | False | 2.4 | False | 20 | 0.43 | 7.6 | 7.4 | 7.8 | True | 164298.45 | 158750.92 | 215401.99 | 158529.19 | 150474.91 | False | 51.5 | 63.92 | 53.79 | 50.19 | 44.2 | 3.3 | 4.1 | 4.1 | 3.7 | 44.8 | 44.8 | 25.4 | NA | -1.4 | False,False;False,False;False,False | [True, False, False] | ['2025-11-04', 832.4, '2026-03-24', 545.5] | 710.15 | Dec 2025:09/02/2026,Sep 2025:12/11/2025,Jun 2025:13/08/2025 | Supriya Lifescience Limited | -8.6 | 4.8 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=585d7f44-4faf-41d5-ae35-e95cfbb287a2.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=980590cc-304e-4c6f-a027-74dbbb48480e.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/f43b1341-6a7f-425c-80a9-4b8b6887590c.pdf | 6.1 | 9.1 | 13.4 | 15.1 | ['DAILY', '2026-04-09', '2026-04-08'] | 49.68 | 50.43 | 34.79 | 50.38 | 46.78 | 46.15 | 44.64 | 36.93 | -1.5 | 6.2 | 6.17 | 6.27 | 4.32 | 6.26 | 5.81 | 5.73 | 5.55 | 4.59 | -1.6 | 6.2 | 23.35 | 14.8 | 206.44 | 199.83 | 145.07 | 184.11 | 185.65 | 166.1 | 160.63 | 158.18 | 3.3 | 11.2 | 17.45 | 34.92 | 36.36 | 35.64 | 36.71 | 35.52 | 38.96 | 38.94 | 35.09 | -4 | -1.7 | Dec 2025 | 20.75 | 27.46 | 0 | 35.9 | 27.3 | -0.27 | -0.22 | 0 | 3.7 | 25.47 | 25.4 | Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti | 68.3 | 21.49 | 5.19 | 5 | 68.3 | 5.46 | 5.22 | 4.68 | 4968.71 | 18.07 | 6.76 | |||||||
| 43 | 46 | 67 | 66 | 09/09/2025 | Pharmaceuticals | 411 | -3.1 | -1.9 | 7 | -2.6 | -20.3 | -25.7 | 31.3 | 15.2 | DAILY | 106.03 | NA | NA | 102.42 | 100.33 | NA | 103.16 | 102.62 | 102.7 | 104.63 | 1.5 | False | False | 1.41 | NA | False | False | False | NA | Healthcare | 36.4 | False | False | False | False | True | 12/03/2026 | False | 4 | False | 20 | 1.8 | 1.8 | 1.1 | 1.2 | True | 148157.3 | 85568.98 | NA | 109973.47 | 130571.06 | False | NA | 42.77 | 47.53 | 48.01 | 30.3 | 5.2 | 4.7 | 5 | 4.6 | 8 | 8 | 31.3 | NA | -0.3 | False,False;False,False;False,False | [False, False, False] | ['2025-09-23', 154.4, '2026-03-16', 92.0] | 109.43 | Dec 2025:10/02/2026,Sep 2025:11/11/2025,Jun 2025:26/09/2025 | Amanta Healthcare Limited | -0.9 | 5.7 | Jun 2025:NA,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/56071f05-5b99-495e-9663-52c5af368ba1.pdf | 7.4 | 9.7 | 14.9 | 18.6 | 4.63 | 1.21 | 3.51 | 5.96 | 4.28 | 2.26 | -0.36 | NA | 282.6 | 8.2 | 1.19 | 0.31 | 1.22 | 2.07 | 1.48 | 0.78 | -0.13 | NA | 283.9 | -19.6 | 3.64 | 1.35 | 74.49 | 70.89 | 65.31 | 72.06 | 67.81 | 66.73 | 68.1 | NA | 5.1 | 9.9 | 8.3 | 20.62 | 20.67 | 22.81 | 26.31 | 22.21 | 20.8 | 19.68 | NA | -0.2 | -7.2 | Dec 2025 | 12.99 | 14.8 | 0.88 | 22.59 | 22.1 | 0.1 | -0.1 | 0 | 0.63 | 22.28 | 21.16 | NA | 63.56 | 24.09 | 1.1 | 11.24 | 63.56 | 1 | 11.34 | 1.95 | 498.54 | 7.58 | 1.76 | |||||||
| 44 | 45 | 78 | 78 | 27/07/2017 | Pharmaceuticals | 53 | 0.3 | 21 | 10.2 | 2.6 | -19 | -22.3 | 42 | 29.6 | DAILY | 33.18 | 38.37 | 36.08 | 32.48 | 29.76 | 37.92 | 31.64 | 30.36 | 30.33 | 30.48 | 0.1 | False | False | 0.87 | NA | False | False | False | 83.8 | Healthcare | 53.2 | False | False | False | False | False | False | 4.9 | False | 20 | 1.1 | 0.1 | 0.4 | 0.3 | True | 19813.15 | 59255.36 | 36771.78 | 35610.26 | 28136.45 | False | 52.1 | 28.3 | 37.33 | 41.76 | 4.3 | 8.4 | 7 | 6.4 | 6 | 11.2 | 11.2 | 90.7 | NA | 3.4 | False,False;False,False;False,False | [True, False, False] | ['2025-06-06', 57.2, '2026-03-30', 25.6] | 35.91 | Dec 2025:13/02/2026,Sep 2025:13/11/2025,Jun 2025:12/08/2025 | Biofil Chemicals & Pharmaceuticals Limited | -7.6 | 4.4 | Jun 2025:NA | 17.7 | 24.6 | 28.2 | 28.2 | ['DAILY', '2026-04-09', '2026-04-08'] | 0.08 | 0.08 | 2.41 | 0.2 | 0.16 | 0.02 | 0.17 | 0.25 | 0 | -50 | 0.05 | 0.05 | 1.48 | 0.12 | 0.1 | 0.01 | 0.1 | 0.15 | 0 | -50 | 0.34 | 0.44 | 0.86 | 13.54 | 6.43 | 8.35 | 14.2 | 2.41 | 8.44 | 15.2 | -93.6 | -93.9 | 2.38 | 10.47 | 0.89 | 0.16 | 1.32 | 2.18 | 4.98 | 3.67 | -0.26 | 1076.4 | 380.3 | Dec 2025 | 3.03 | 4.12 | 0 | 1.13 | 19.5 | 0 | 0 | 0 | -2.71 | 165.9 | 134.53 | Biofil Chemicals and Pharmaceuticals Limited manufactures and trades in pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and plastic drippers and caps for packing applications. It also provides job work service for manufacturing pharmaceutical drugs. Biofil Chemicals and Pharmaceuticals Limited was incorporated in 1985 and is based in Indore, India. **Website:** [https://www.biofilgroup.net](https://www.biofilgroup.net) | 46.79 | 53.12 | 0 | 0.08 | 46.79 | 0 | 0.08 | 2.54 | 53.54 | 15.12 | 1.83 | |||||||
| 45 | 43 | 26 | 47 | 13/03/2015 | Pharmaceuticals | 1215 | 0.3 | 0.6 | -1.6 | -8.5 | -18.8 | -12.7 | 39.2 | 15.3 | DAILY | 1428.5 | 1703.41 | 1636.79 | 1474.56 | 1398.14 | 1647.62 | 1463.54 | 1415.07 | 1413.28 | 1402.23 | 0.8 | False | False | 0.39 | NA | False | False | False | 55.9 | Healthcare | 46.3 | False | False | False | False | False | False | 1.5 | False | 20 | 0.33 | 1.2 | 1 | 0.9 | True | 5676.55 | 4770.86 | 7800.06 | 4807.81 | 4605.85 | False | 68.4 | 39.46 | 42.88 | 44.49 | 15.7 | 3.4 | 4.2 | 4.5 | 3.9 | 8.8 | 8.8 | 57.7 | NA | 1.4 | False,False;False,False;False,False | [False, False, False] | ['2025-08-04', 2350.0, '2026-03-30', 1239.3] | 1585 | Dec 2025:30/01/2026,Sep 2025:12/11/2025,Jun 2025:01/08/2025 | Hester Biosciences Limited | -3.7 | 9.8 | Jun 2025:NA | 4.8 | 9.4 | 15.7 | 20.6 | [1455.0, '16/03/2026', 'DAILY'] | ['DAILY', '2026-04-09', '2026-04-08'] | 9.32 | 14.33 | 17.29 | 1.54 | 11.41 | 8.39 | 7.49 | 6.4 | -35 | -18.3 | 10.31 | 16.99 | 19.33 | 1.52 | 13.71 | 9.64 | 7.45 | 5.82 | -39.3 | -24.8 | 32.31 | 22.21 | 77.42 | 70.97 | 84.11 | 81.93 | 63.22 | 83.69 | 82.27 | 79.26 | 9.1 | 22.5 | 11.16 | 22.99 | 16.51 | 27.12 | 23.41 | 8.02 | 22.89 | 21.45 | 20.09 | 39.2 | 186.7 | Dec 2025 | 9.18 | 9.71 | 0.63 | 22.74 | 29.7 | -0.14 | -0.01 | 0 | -2.74 | 34.64 | 51.67 | Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through Poultry Healthcare, Animal Healthcare, and Petcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers livestock vaccines for goat pox, peste des petits ruminants, brucella abortus, contagious bovine pleuropneumonia, CCPP, and lumpy skin diseases; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, coat nutrition, grooming aids, and anti-infective formulations. Additionally, the company provides seroprofiling kits; diagnostic labs for poultry flocks; and mastitis control programs for cattle; as well as engages in manufacturing and trading of goods. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India. **Website:** [https://www.hester.in](https://www.hester.in) | 53.73 | 45.88 | 0.38 | 0 | 53.73 | 0.52 | 0.01 | 3.6 | 1423.28 | 17.13 | 4.53 | ||||||
| 46 | 41 | 30 | 30 | 01/07/2002 | Pharmaceuticals | 7971 | -0.9 | 0.5 | -0.6 | -13.9 | -20.9 | -8 | 28.7 | 2 | DAILY | 4802.1 | 5739.25 | 5645.46 | 5031.32 | 4854.76 | 5468.25 | 5038.41 | 4871.62 | 4866.84 | 4828.91 | 6.8 | False | False | 0.8 | NA | False | False | False | 136.8 | Healthcare | 48.2 | False | False | False | False | False | False | 2.3 | False | 20 | 1.36 | 7.2 | 8.6 | 6 | False | 14065.6 | 16855.58 | 12690.58 | 14727.26 | 15452.94 | False | 10.1 | 51.99 | 43.82 | 41.57 | 38.8 | 2.3 | 2.3 | 2.3 | 2.4 | 4 | 4 | 36 | 26/05/2026 | 0.9 | False,False;False,False;False,False | [False, False, False] | ['2025-08-29', 6739.0, '2026-04-06', 4707.0] | 5498 | Dec 2025:06/02/2026,Sep 2025:05/11/2025,Jun 2025:01/08/2025 | Procter & Gamble Health Limited | -7.5 | 7.9 | Jun 2025:NA | 3.4 | 4.8 | 4.8 | 5.9 | 77.59 | 88.54 | 66.18 | 61.18 | 90.9 | 82.33 | 16.78 | 46.56 | -12.4 | -14.6 | 46.74 | 53.34 | 39.87 | 36.86 | 54.76 | 49.6 | 10.11 | 28.05 | -12.4 | -14.6 | 141.22 | 138.24 | 373.86 | 324.92 | 338.74 | 310.99 | 309.77 | 313.41 | 283.88 | 252.48 | 15.1 | 20.7 | 0.16 | 29.55 | 37.02 | 26.67 | 26.02 | 39.85 | 36.39 | 17 | 26.71 | -20.2 | -25.8 | Dec 2025 | 36.42 | 47.75 | 0.01 | 29.81 | 27.2 | -0.27 | -0.06 | 0 | 2.77 | 25.69 | 36.99 | Procter & Gamble Health Limited engages in the manufacture and marketing of pharmaceuticals and chemical products in India and internationally. The company provides over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. The company was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India BV. **Website:** [https://www.pghealthindia.com](https://www.pghealthindia.com) | 51.82 | 27.37 | 6.97 | 13.84 | 51.82 | 7.24 | 13.9 | 12.86 | 7701.19 | 18.4 | 5.71 | ||||||||
| 47 | 37 | 98 | 40 | 24/11/2025 | Pharmaceuticals | 1436 | -2.4 | 2.1 | 31.9 | -10.6 | -19.1 | -20.5 | 29.2 | 43.1 | DAILY | 1417 | 1608.96 | 1551.45 | 1235.47 | 1214.31 | 1523.65 | 1279.31 | 1268.09 | 1271.94 | 1351.17 | 2.1 | False | False | 0.36 | NA | False | False | False | 246.9 | Healthcare | 35.1 | False | False | False | False | False | False | 5.8 | False | 20 | 0.39 | 1.4 | 1.3 | 1 | True | 17160.9 | 15679.7 | 9786.55 | 15488.24 | 17806.11 | False | 0.3 | 43.85 | 38.4 | 37.97 | 43.9 | 12.6 | 9.2 | 8.4 | 7.3 | 13.6 | 13.6 | 39.1 | NA | 1.5 | False,False;False,False;False,False | [False, False, False] | ['2025-08-18', 2000.0, '2026-02-25', 990.1] | 1549 | Dec 2025:14/02/2026 | Beta Drugs Limited | 3.2 | 21.2 | Jun 2025:NA,Sep 2025:https://nsearchives.nseindia.com/corporate/BETA_07112025091924_investor_presntation.pdf | 13.1 | 25.6 | 33.9 | 36.9 | 8.52 | 12.22 | NA | NA | 8.95 | 24.44 | NA | NA | -30.3 | -4.8 | 8.4 | 12.11 | 17.81 | NA | 8.86 | 24.2 | NA | NA | -30.6 | -5.2 | 42.02 | 36.08 | 87.27 | 103.39 | NA | NA | 88.29 | 180.3 | NA | NA | -15.6 | -1.2 | 31.89 | 19.46 | 20.6 | NA | NA | 20.91 | 21.53 | NA | NA | -5.5 | -6.9 | Dec 2025 | 25.86 | 27.04 | 0.66 | 19.92 | 34.1 | 0.02 | 0.25 | -1.83 | 1.47 | 42.17 | 33.23 | NA | 64.9 | 32.06 | 1.16 | 2.15 | 66.73 | 1.14 | 1.9 | 6.47 | 1459.59 | 16.64 | 3.78 | ||||||||
| 48 | 36 | 43 | 42 | 20/09/2011 | Pharmaceuticals | 14155 | -0.8 | 9.7 | 2.1 | -10 | -22.6 | -14.3 | 35 | 13.3 | DAILY | 720.15 | 874.87 | 839.34 | 730.1 | 681.52 | 837.6 | 726.09 | 692.41 | 691.55 | 689.66 | 8 | False | False | 5.95 | NA | False | False | False | 43.2 | Healthcare | 30.3 | False | False | False | False | True | 27/03/2026 | False | 1.9 | False | 20 | 0.35 | 10.2 | 7.1 | 9.8 | True | 117132.15 | 81450.76 | 146626.72 | 100580.66 | 119453.99 | False | 60 | 36.55 | 34.43 | 34.28 | 20 | 4.1 | 3.9 | 3.6 | 3.4 | 2.4 | 2.4 | 44.8 | NA | 0 | False,False;False,False;False,False | [True, False, False] | ['2025-06-30', 1107.9, '2026-03-23', 635.8] | 810.45 | Dec 2025:05/02/2026,Sep 2025:04/11/2025,Jun 2025:05/08/2025 | Alembic Pharmaceuticals Limited | -11.1 | 2.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=83d227fb-47b0-46f6-8347-601c06bb1b4c.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7517e5c0-3e56-45fc-acd9-d392c6e0f2a9.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/46c93f24-1700-455c-b9cd-ab997c99dfbc.pdf | 12.8 | 13.8 | 13.8 | 15 | [737.1, '06/03/2026', 'DAILY'] | ['DAILY', '2026-04-09', '2026-04-08'] | 131.95 | 183.71 | 153.63 | 156.63 | 137.7 | 153.14 | 134.54 | 178.21 | -28.2 | -4.2 | 6.76 | 9.4 | 7.85 | 7.98 | 7.04 | 7.8 | 6.85 | 9.07 | -28.1 | -4 | 29.68 | 31.33 | 1876.31 | 1910.15 | 1710.72 | 1769.64 | 1692.74 | 1647.98 | 1561.73 | 1516.98 | -1.8 | 10.8 | 7.69 | 15.54 | 16.53 | 16.42 | 15.33 | 15.37 | 14.52 | 15.16 | 17.12 | -6 | 1.1 | Dec 2025 | 11.38 | 13.05 | 0.28 | 15.96 | 22.5 | 0.19 | -0.13 | 0 | 6.68 | 26.63 | 29.9 | Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India. **Website:** [https://alembicpharmaceuticals.com](https://alembicpharmaceuticals.com) | 69.74 | 9.84 | 4.23 | 16.17 | 69.74 | 4.04 | 16.3 | 2.66 | 15432.23 | 12.82 | 2.12 | |||||
| 49 | 36 | 7 | 24 | 01/01/1996 | Pharmaceuticals | 98904 | 0.7 | 2.7 | -7.6 | -16.5 | -19.1 | -13.5 | 26.8 | 5 | DAILY | 1224.4 | 1464.06 | 1445.79 | 1300.61 | 1251.6 | 1421.8 | 1302.76 | 1247.95 | 1245.7 | 1221.86 | 221 | False | False | 57.18 | Nifty Pharma,Nifty Healthcare,Nifty Manufacturing,Nifty 100,Nifty 50,Nifty 500 | False | False | False | 106.2 | Healthcare | 70.8 | False | False | False | False | False | False | 1.5 | True | No Band | 1.43 | 166.5 | 160.2 | 149.5 | True | 1777563.25 | 1714091.62 | 1627619.59 | 1786575.88 | 1960304.8 | False | 11.5 | 44.51 | 38.12 | 36.37 | 37.9 | 2.1 | 2.3 | 2.2 | 2.1 | 12 | 12 | 28.1 | 13/05/2026 | -0.1 | False,False;False,False;False,False | [True, False, False] | ['2025-10-23', 1673.0, '2026-04-02', 1165.7] | 1358.1 | Dec 2025:23/01/2026,Sep 2025:30/10/2025,Jun 2025:25/07/2025 | Cipla Limited | -6.9 | 5.4 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc6f1835-1653-4507-ac88-eb31eff815c9.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9feb721-cda2-4afe-857c-4ef41a0163e6.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/d0318e3b-b31b-41a5-a9ae-adf3337e2e7c.pdf | 3.7 | 5.3 | 7.3 | 13.1 | ['WEEKLY', '2026-04-06', '2026-03-30'] | 674.25 | 1353.37 | 1291.61 | 1214.14 | 1574.59 | 1305.01 | 1175.46 | 931.87 | -50.2 | -57.2 | 8.37 | 16.73 | 16.06 | 15.13 | 19.45 | 16.13 | 14.58 | 11.63 | -50 | -57 | 65.28 | 51.05 | 7074.48 | 7589.44 | 6957.47 | 6729.69 | 7072.97 | 7051.02 | 6693.94 | 6163.24 | -6.8 | 0 | 9.97 | 17.74 | 24.97 | 25.56 | 22.85 | 28.12 | 26.74 | 25.63 | 21.35 | -29 | -36.9 | Dec 2025 | 17.77 | 22.72 | 0.01 | 22.81 | 21.8 | -0.61 | 0.47 | 0 | 0.8 | 36.57 | 28.21 | Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India. **Website:** [https://www.cipla.com](https://www.cipla.com) | 29.21 | 16.12 | 23.93 | 30.45 | 29.21 | 24.54 | 29.98 | 3 | 98584.56 | 13.16 | 3.48 | |||||||
| 50 | 30 | 26 | 5 | 01/04/2005 | Pharmaceuticals | 3042 | -1 | 11.1 | -1.6 | -28.6 | -32.8 | 13.5 | 41.7 | 24.1 | DAILY | 279.19 | 369.98 | 373.06 | 299.2 | 270.44 | 341.2 | 300.25 | 273.51 | 272.64 | 266.55 | 3.2 | False | False | 3.18 | NA | False | False | False | 54.1 | Healthcare | 29.1 | False | False | False | False | False | False | 3.4 | False | 20 | 0.32 | 4.3 | 3.3 | 4 | False | 119944.35 | 90307.04 | 138270.38 | 109426.74 | 112712.28 | False | 29.7 | 55.17 | 36.29 | 29.3 | 63.9 | 5 | 5.8 | 6.1 | 5.5 | 32 | 32 | 41.7 | NA | 1.4 | False,False;False,False;False,False | [True, False, False] | ['2025-10-27', 479.0, '2026-03-30', 225.1] | 340.75 | Dec 2025:05/02/2026,Sep 2025:10/11/2025,Jun 2025:01/08/2025 | Gujarat Themis Biosyn Limited | -15 | 7.8 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1776c04-b5dc-4d66-a742-07c82bd921e5.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db6134ec-e213-4991-8912-9b4eca8a2d39.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/fd6da361-2bce-497d-936b-de6a8697c8fb.pdf | 10.7 | 17.8 | 21.4 | 26.6 | 12.46 | 14.26 | 9.06 | 12 | 12.97 | 10.57 | 13.24 | 15.89 | -12.6 | -3.9 | 1.14 | 1.31 | 0.83 | 1.1 | 1.19 | 0.97 | 1.21 | 1.46 | -13 | -4.2 | 4.48 | 5.43 | 43.37 | 42.35 | 35.87 | 37.74 | 39.52 | 34.72 | 38.83 | 42.01 | 2.4 | 9.7 | 12.12 | 49.11 | 49.45 | 38.81 | 42.5 | 47.72 | 44.33 | 47.8 | 49.8 | -0.7 | 2.9 | Dec 2025 | 21.69 | 27.29 | 0.27 | 45.31 | 63.7 | -0.99 | 0 | 0 | 16.76 | 61.23 | 25.62 | Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India. **Website:** [https://www.gtbl.in](https://www.gtbl.in) | 70.86 | 26 | 1.96 | 1.17 | 70.86 | 2.95 | 1.17 | 11.5 | 3097.05 | 41.26 | 19.44 | ||||||||
| 51 | 29 | 15 | 27 | 05/11/2009 | Pharmaceuticals | 1535 | -0.5 | 4 | -4.7 | -15.1 | -24.9 | -16.5 | 32.9 | 9.2 | DAILY | 530.95 | 666.51 | 655.1 | 571.33 | 523.55 | 640.51 | 564.77 | 531.15 | 529.91 | 520.54 | 1.6 | False | False | 1.55 | NA | False | False | False | 98.1 | Healthcare | 53.5 | False | False | False | False | True | 23/03/2026 | True | 1.5 | False | 20 | 0.22 | 1.9 | 1.2 | 1 | True | 30987 | 19409.26 | 21003.15 | 22403.24 | 26820.53 | False | 50.7 | 36.06 | 30.08 | 28.34 | 38.3 | 3.4 | 3.9 | 3.9 | 3.4 | 8 | 8 | 48.2 | NA | 0.8 | False,False;False,False;False,False | [True, False, False] | ['2025-09-08', 791.0, '2026-03-30', 486.0] | 648.4 | Dec 2025:03/02/2026,Sep 2025:10/11/2025,Jun 2025:12/08/2025 | Amrutanjan Health Care Limited | -8.9 | 12.9 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94ad9121-9750-47f5-8bfe-8653285e1690.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=adfd1b4c-9c93-446e-a680-a6177b41e635.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/13d9ebb9-3522-41c3-be19-53d2b0fc79bd.pdf | 6.3 | 9.4 | 10 | 17.5 | ['DAILY', '2026-04-09', '2026-04-08'] | 19.45 | 13.96 | 8.31 | 15.18 | 19.25 | 11.8 | 4.62 | 13.66 | 39.3 | 1 | 6.73 | 4.83 | 2.87 | 5.25 | 6.66 | 4.08 | 1.6 | 4.72 | 39.3 | 1.1 | 17.58 | 15.55 | 141.04 | 117.7 | 94.05 | 135.41 | 122.75 | 109.92 | 83.74 | 127.06 | 19.8 | 14.9 | 11.56 | 17.85 | 14.04 | 8.97 | 13.07 | 19.02 | 12.37 | 4.24 | 12.78 | 27.1 | -6.2 | Dec 2025 | 16.53 | 22.45 | 0.01 | 13.89 | 27 | -0.11 | 0.1 | 0 | -3 | 19.72 | 40.48 | Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products. The company operates through OTC Products, Beverages, and Others segments. It provides pain management products comprising pain balms and roll-ons; and back pain roll-ons, stick-on patch, body pain gels, and joint muscle sprays. The company offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints. It also provides sanitary napkins for women. In addition, the company offers corn caps; dental gel; hand sanitizers; and juice drinks under the Fruitnik and Fruitnik Electro+ brand names, as well as operates a pain management center. It exports its products to the Middle East, Africa, the Southeast Asia, and internationally. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India. **Website:** [https://www.amrutanjan.com](https://www.amrutanjan.com) | 46.52 | 38.18 | 2.27 | 13 | 46.52 | 2.38 | 12.9 | 4.49 | 1478.3 | 17.29 | 3.03 | ||||||
| 52 | 28 | 78 | 29 | 27/10/2016 | Pharmaceuticals | 123 | -0.1 | 20.4 | 10.2 | -14.3 | -19.3 | -20.8 | 49.5 | 49.6 | DAILY | 57.33 | 68.61 | 64.59 | 54.63 | 50.48 | 65.97 | 54.9 | 52.11 | 52.07 | 52.97 | 0.3 | False | False | 0.59 | NA | False | False | False | 169.6 | Healthcare | 27.3 | False | False | True | 07/04/2026 | True | True | 07/04/2026 | True | 5.4 | False | 10 | 0.25 | 0.6 | 0.3 | 0.2 | True | 46243.35 | 23673.24 | 19289.44 | 35582.2 | 67298.62 | False | 38.6 | 30 | 27.92 | 27.39 | 34.9 | 11.8 | 8.8 | 8.1 | 7.1 | 13.6 | 13.6 | 74.8 | NA | -2.5 | False,False;False,False;False,False | [False, False, False] | ['2025-06-09', 113.5, '2026-03-30', 38.3] | 61.8 | Dec 2025:09/02/2026,Sep 2025:04/11/2025,Jun 2025:07/08/2025 | Krebs Biochemicals and Industries Limited | 1.3 | 21.2 | Jun 2025:NA | 18.6 | 38.2 | 44.1 | 44.1 | -3.13 | -6.14 | -5.32 | -8.27 | -7.74 | -5.76 | -5.17 | -5.85 | 49 | 59.6 | -1.45 | -2.85 | -2.47 | -3.84 | -3.59 | -2.67 | -2.4 | -2.71 | 49.1 | 59.6 | -12.5 | -9.15 | 7.27 | 4.17 | 5.48 | 6.1 | 11.47 | 12.86 | 12.89 | 11.97 | 74.3 | -36.6 | 5.33 | 4.13 | -67.15 | -38.14 | -88.69 | -41.06 | -21.15 | -16.99 | -26.07 | 106.2 | 110.1 | Dec 2025 | NA | -30.09 | NA | -43.44 | -5.4 | 0 | 0 | 0 | NA | -9.88 | NA | Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. The company was incorporated in 1991 and is based in Visakhapatnam, India. **Website:** [https://krebsbiochem.com](https://krebsbiochem.com) | 72.74 | 26.76 | 0.5 | 0 | 72.74 | 0.5 | 0 | NA | 343.69 | -35.65 | 14.93 | ||||||
| 53 | 27 | 81 | 50 | 06/08/2007 | Pharmaceuticals | 145 | -1.3 | 34 | 11.6 | -7.8 | -22.2 | -31.9 | 42.4 | 50.5 | DAILY | 69.36 | 83.14 | 77.48 | 64.19 | 59.32 | 79.67 | 64.2 | 61.02 | 60.98 | 61.92 | 0.3 | False | False | 0.9 | NA | False | False | False | 135.2 | Healthcare | 42.7 | False | False | True | 07/04/2026 | True | True | 07/04/2026 | True | 4.2 | False | 10 | 0.5 | 0.4 | 0.2 | 0.2 | False | 52569.65 | 31703 | 35607.73 | 42081.49 | 64637.82 | False | 67 | 24.98 | 25.12 | 26.53 | 20.6 | 9.2 | 7.2 | 6.3 | 5.6 | 5.6 | 5.6 | 52 | NA | -2.9 | False,False;False,False;False,False | [False, False, False] | ['2025-05-28', 120.5, '2026-03-30', 46.1] | 72.05 | Dec 2025:11/02/2026,Sep 2025:14/11/2025,Jun 2025:13/08/2025 | Alpa Laboratories Limited | -3.7 | 5.7 | Jun 2025:NA | 7.6 | 32.9 | 36.4 | 36.4 | ['DAILY', '2026-04-09', '2026-04-08'] | 1.9 | 0.11 | 11.77 | -2.12 | 8.9 | 7.69 | 5.1 | 3.55 | 1627.3 | -78.7 | 0.9 | 0.05 | 5.59 | -1.01 | 4.23 | 3.65 | 2.42 | 1.69 | 1700 | -78.7 | 9.27 | 7.98 | 29.05 | 26.26 | 19.11 | 39.92 | 26.15 | 24.94 | 21.44 | 23.61 | 10.6 | 11.1 | 5.24 | 5.2 | -8.57 | 2.25 | 0.5 | 2.83 | 13.31 | 2.47 | 14.87 | 160.7 | 83.7 | Dec 2025 | 12.09 | 15.79 | 0 | -0.1 | 12.5 | 0.01 | 0 | 0 | 0.35 | 19.27 | 11.37 | Alpa Laboratories Limited engages in the manufacture and sale of pharmaceutical finished dosage forms in India. The company offers ethical, generic, and over the counter pharmaceutical products in various finished dosage forms, including injections, tablets, capsules, eye and ear drops, creams, gels, and ointments for human and veterinary use. It also provides drugs in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations. The company sells its products through distributors, retail chemists, retail pharmacy stores, and hospitals. It also exports its products to South and Central America, Africa, and Asia, Russia, Ukraine, Kazakhstan, and internationally. The company was founded in 1967 and is based in Indore, India. **Website:** [https://www.alpalabs.in](https://www.alpalabs.in) | 57.29 | 42.35 | 0.36 | 0 | 57.29 | 0.35 | 0 | 0.8 | 145.73 | 7.97 | 1.27 | |||||
| 54 | 24 | 6 | 13 | 23/01/2025 | Pharmaceuticals | 15768 | 2.4 | -2.1 | -9.2 | -21.9 | -27.2 | -7.4 | 38.8 | 30.2 | DAILY | 1375.7 | 1702.15 | 1616.63 | 1325.91 | 1429.25 | 1594.44 | 1419.28 | 1401.44 | 1401.56 | 1395.23 | 55.4 | False | False | 8.03 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 143.7 | Healthcare | 70.1 | False | False | False | False | False | False | 2.6 | False | 20 | 0.26 | 63 | 70.3 | 52.4 | True | 390475.1 | 430901.5 | 350126.45 | 357382.27 | 358467.72 | False | 68 | 42.28 | 33.29 | 28.22 | 64.7 | 4.3 | 6.1 | 5.8 | 5.8 | 32 | 32 | 38.8 | NA | 1.2 | False,False;False,False;False,False | [False, False, False] | ['2025-06-18', 2248.0, '2026-01-30', 1057.0] | 1514.9 | Dec 2025:23/01/2026,Sep 2025:11/11/2025,Jun 2025:04/08/2025 | Onesource Specialty Pharma Limited | -4 | 7.7 | Jun 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/aae0592d-87dd-4bd0-82ca-b15f46e9bef3.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14e30e87-875e-4221-a841-51cbdcec660a.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/dc707f76-4ffa-419e-bb2a-2d33e8875ccf.pdf | 6.9 | 8.5 | 11.7 | 20.2 | ['DAILY', '2026-04-09', '2026-04-08'] | -88.7 | 10.49 | -0.19 | 98.5 | -68.85 | -42.08 | -5.55 | -40.17 | -945.6 | -28.8 | -7.74 | 0.92 | -0.02 | 8.61 | -6.02 | NA | NA | NA | -941.3 | -28.6 | -1.57 | NA | 290.34 | 375.76 | 327.27 | 425.95 | 392.56 | 334.05 | 292.29 | 73.14 | -22.7 | -26 | NA | 5.97 | 28.34 | 27.04 | 42.85 | 36.14 | 23.14 | 22 | -3.83 | -78.9 | -83.5 | Dec 2025 | 3.34 | 5.53 | 0.22 | 27.82 | 777.2 | -0.15 | 0.32 | 0.16 | 14.81 | -44.43 | 282.96 | OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India and internationally. The company provides end-to-end CDMO services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. OneSource Specialty Pharma Limited was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. The company was incorporated in 2007 and is based in Bengaluru, India. **Website:** [https://www.onesourcecdmo.com](https://www.onesourcecdmo.com) | 29.93 | 32.01 | 19.24 | 18.8 | 29.77 | 19.39 | 18.48 | 2.67 | 16920.41 | 41.21 | 11.92 | |||||||
| 55 | 21 | 18 | 15 | 01/07/2002 | Pharmaceuticals | 1971 | -3.2 | -0.5 | -3.6 | -20.8 | -26.5 | -26.2 | 44.7 | 10.1 | DAILY | 321.9 | 388.22 | 379.04 | 341.49 | 327.09 | 373.66 | 339.63 | 327 | 326.6 | 323.64 | 4.1 | False | False | 1.69 | NA | False | False | False | 25.8 | Healthcare | 27.5 | False | False | False | False | False | False | 5.3 | False | 20 | 0.89 | 3.3 | 3 | 19 | False | 124580.9 | 115656.48 | 478229.75 | 297157.86 | 120399.24 | False | 36.6 | 48.7 | 34.85 | 31.6 | 77.2 | 3.9 | 4.8 | 4.8 | 4.8 | 26.4 | 26.4 | 44.7 | NA | -0.2 | False,False;False,False;False,False | [False, False, False] | ['2025-04-30', 581.9, '2026-03-30', 292.4] | 362.25 | Dec 2025:11/02/2026,Sep 2025:14/11/2025,Jun 2025:14/08/2025 | Panacea Biotec Limited | -9.2 | 6.4 | Jun 2025:NA | 6.5 | 7.4 | 14 | 19.9 | 3.89 | -14.01 | 3.96 | -1.99 | 4.44 | 4.71 | -15.88 | -1.99 | 127.8 | -12.4 | 0.65 | -2.27 | 0.66 | -0.31 | 0.74 | 0.78 | -2.58 | -0.32 | 128.6 | -12.2 | -1.37 | -0.19 | 165.19 | 141.13 | 166.7 | 132.53 | 163.49 | 147.35 | 115.72 | 136.46 | 17 | 1 | 0.55 | 7.11 | -12.61 | -0.71 | -20.28 | 4.87 | 4.75 | -12.09 | -4.43 | 156.4 | 46 | Dec 2025 | -4.92 | -4.57 | 0.03 | -5.63 | -253.5 | 0.3 | 0.05 | 0 | NA | 123.81 | NA | Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as transplantation, renal disease, oncology, respiratory, pain management, diabetes and cardiovascular management, gastro-intestinal care, nephrology, osteoporosis management, orthopedics, pain management, and fever; and betacoronavirus, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, hepatitis A, and varicella vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc for the manufacture and supply of Azacitidine injection; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India. **Website:** [https://www.panaceabiotec.com](https://www.panaceabiotec.com) | 72.48 | 24.31 | 1.36 | 1.85 | 72.48 | 1.06 | 1.8 | 2.39 | 1917.7 | -171.68 | 3.17 | ||||||||
| 56 | 15 | 52 | 16 | 01/04/2005 | Pharmaceuticals | 160 | 0.2 | 0.8 | 3.7 | -20 | -36.2 | -26.7 | 47.9 | 13.1 | DAILY | 154.28 | 193.29 | 186.41 | 155.62 | 149.23 | 185.97 | 157.14 | 151.11 | 151 | 151.18 | 0.1 | False | False | 0.51 | NA | False | False | False | 141.6 | Healthcare | 48.7 | False | False | False | False | False | False | 3.7 | False | 20 | 0.22 | 0.2 | 0.5 | 0.3 | True | 8644.15 | 20382.16 | 17746.2 | 19334.24 | 15357.91 | False | 34.5 | 27.3 | 25.66 | 24.69 | 72 | 4.8 | 5.8 | 5.5 | 5.9 | 9.6 | 9.6 | 47.9 | NA | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-09-26', 296.0, '2026-03-27', 136.4] | 165.97 | Dec 2025:13/02/2026,Sep 2025:13/11/2025,Jun 2025:04/08/2025 | Natural Capsules Limited | -7 | 5.4 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bbd4e547-ce46-43d1-bbff-2f33392afaea.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=01b9f0b0-5c6c-4c17-b304-23ceb20143f3.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/5cb0c9e5-183e-4ecf-9d07-77d9296a3aa9.pdf | 8.1 | 8.5 | 14.1 | 14.8 | [157.2, '13/03/2026', 'DAILY'] | ['DAILY', '2026-04-09', '2026-04-08']['WEEKLY', '2026-04-06', '2026-03-30'] | -7.12 | -6.99 | -5.58 | 0.52 | 0.11 | -0.61 | 0.6 | 0.97 | -1.9 | -6572.7 | -6.89 | -6.76 | -5.4 | 0.5 | 0.11 | -0.6 | 0.64 | 1.04 | -1.9 | -6363.6 | 0.6 | 5.95 | 37.75 | 45.8 | 45.2 | 44.97 | 43.83 | 41.22 | 39.18 | 40.22 | -17.6 | -13.9 | 22.38 | -6.15 | -1.94 | 0.71 | 9.76 | 9.74 | 10.92 | 11.15 | 10.22 | -217 | -163.1 | Dec 2025 | 0.28 | 2.67 | 0.46 | 0.86 | -8.3 | 0 | 0 | 0 | NA | -5.6 | 31.16 | Natural Capsules Limited engages in manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally. The company offers bovine spongiform encephalopathy and transmissible spongiform encephalopathy free gelatin, shiny gelatin, sodium lauryl sulfate free gelatin, halal certified gelatin, fast release gelatin, printed gelatin/cellulose, vegetarian, and enteric capsule shells. It is also involved in formulating pharmaceutical dosage forms in capsule dosage form. The company also exports its products. Natural Capsules Limited was incorporated in 1993 and is based in Bengaluru, India. **Website:** [https://www.naturalcapsules.com](https://www.naturalcapsules.com) | 51.26 | 48.74 | 0 | 0 | 51.26 | 0 | 0 | 0.65 | 266.66 | 96.27 | 1.53 | ||||||
| 57 | 13 | 68 | 24 | 02/04/2007 | Pharmaceuticals | 759 | 0.8 | 4.1 | 7.2 | -16.4 | -40.1 | -28.9 | 53.1 | 27 | DAILY | 82.46 | 105.86 | 102.13 | 81.63 | 76.64 | 109.52 | 82.53 | 78.04 | 77.94 | 77.98 | 0.9 | False | False | 3.03 | NA | False | False | False | 50.4 | Healthcare | 32.9 | False | False | False | False | False | False | 3 | False | 20 | 0.57 | 1.5 | 1.3 | 1.1 | True | 124239.65 | 105424.48 | 183618.52 | 117893.01 | 119153.45 | False | 52.2 | 8.22 | 10.61 | 11.31 | 7.1 | 6 | 6.5 | 6.2 | 5.8 | 16 | 16 | 74 | NA | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-05-19', 176.0, '2026-03-30', 64.9] | 91.57 | Dec 2025:13/02/2026,Sep 2025:13/11/2025,Jun 2025:01/08/2025 | Themis Medicare Limited | -9.2 | 5.7 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46567f69-d8bf-4977-99f3-b7eec5435322.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a7910e5-76b1-4826-9775-60cc18c4884a.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/bfafc8d0-d205-47f1-80d2-c3115f7c91d7.pdf | 8.8 | 15.7 | 23.1 | 23.5 | ['DAILY', '2026-04-09', '2026-04-08'] | 10.09 | -3.62 | -14.22 | -9.66 | 0.52 | 14.29 | 24.68 | 6.64 | 378.7 | 1840.4 | 1.1 | -0.39 | -1.54 | -1.05 | 0.06 | 1.55 | 2.68 | 0.72 | 382.1 | 1733.3 | 3.24 | 4.73 | 90.13 | 77.99 | 97.58 | 71.7 | 93.81 | 117.01 | 122.99 | 97.82 | 15.6 | -3.9 | 15 | 10.87 | -3.97 | -10.47 | -10.74 | 6.36 | 14.64 | 23.73 | 9.5 | 373.8 | 70.9 | Dec 2025 | 7.65 | 10.37 | 0.25 | -3.33 | -43.6 | -0.01 | 0 | -0.04 | NA | 18.74 | 24.18 | Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. The company offers active pharmaceutical ingredients (APIs) and formulations for use in various therapeutic areas, including anti-tuberculosis, anti-malarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition, anaesthesia, gynecology, and orthopedics. It also offers anti-inflammatory drugs and other drugs. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is headquartered in Mumbai, India. **Website:** [https://www.themismedicare.com](https://www.themismedicare.com) | 67.11 | 32.84 | 0.05 | 0.01 | 67.15 | 0.06 | 0.01 | 2 | 833.48 | 253.34 | 2.47 | |||||||
| 58 | 11 | 9 | 25 | 01/07/2002 | Pharmaceuticals | 7976 | 1.3 | 6.1 | -6.8 | -16 | -26.5 | -42.7 | 48.4 | 9.6 | DAILY | 3463.5 | 4633.96 | 4280.33 | 3757.94 | 3394.04 | 4504.87 | 3684.74 | 3449.53 | 3440.3 | 3368.97 | 11.1 | False | False | 0.91 | NA | False | False | False | 172.7 | Healthcare | 39.6 | False | False | False | False | False | False | 2.9 | False | 20 | 1.42 | 23.4 | 16.7 | 13.1 | False | 33299.35 | 23682.6 | 19071.07 | 27649.71 | 36940.26 | False | 17.5 | 13.41 | 13.37 | 12.8 | 42.1 | 3.1 | 3.1 | 2.9 | 2.5 | 0.8 | 0.8 | 67.1 | NA | 0.9 | False,False;False,False;False,False | [False, False, False] | ['2025-04-24', 6717.0, '2026-03-27', 3160.0] | 4134.7 | Dec 2025:25/02/2026,Sep 2025:29/10/2025,Jun 2025:31/07/2025 | Sanofi India Limited | -16.2 | 0.1 | Jun 2025:NA,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27dc448a-dc8f-47e7-aa83-200527fa6db0.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/8349d6b7-eb1e-4dca-82c9-a1846ddd6044.pdf | 5.1 | 8.8 | 9.2 | 16.1 | 61.7 | 76 | 69.5 | 119.5 | 91.3 | 82.2 | 103.4 | 136.6 | -18.8 | -32.4 | 26.83 | 33.04 | 30.22 | 51.96 | 39.7 | 35.74 | 44.96 | 59.39 | -18.8 | -32.4 | 142.04 | 179.78 | 419.8 | 475.4 | 406.3 | 535.9 | 514.9 | 524 | 463.5 | 510.8 | -11.7 | -18.5 | -8.74 | 21.51 | 28.23 | 23.36 | 32.08 | 22.98 | 22.84 | 24.96 | 26.84 | -23.8 | -6.4 | Dec 2025 | 43.04 | 57.53 | 0.02 | 26.74 | 24.4 | -0.02 | -0.98 | 0 | -1.77 | 32.27 | 21.14 | Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH. **Website:** [https://www.sanofi.com/en/india/investors](https://www.sanofi.com/en/india/investors) | 60.4 | 12.75 | 5.55 | 21.3 | 60.4 | 5.57 | 22.28 | 10.63 | 7713.75 | 15.1 | 4.2 | ||||||||
| 59 | 10 | 95 | 63 | 05/09/2011 | Pharmaceuticals | 210 | -0.2 | 34.1 | 22.4 | -3.6 | -45.3 | -42.2 | 56.4 | 97.2 | DAILY | 71.57 | 107.73 | 93.96 | 62.75 | 55.93 | 94.69 | 63.98 | 58.94 | 58.9 | 60.82 | 1.5 | False | False | 1.4 | NA | False | False | False | 304.3 | Healthcare | 47.4 | False | False | True | 07/04/2026 | True | True | 07/04/2026 | True | 4.2 | False | 10 | 0.42 | 2.5 | 1.5 | 1 | True | 255392.5 | 151752.24 | 94478.81 | 196509.53 | 321343.35 | False | 0 | 9.49 | 7.45 | 9.53 | 65.5 | 11.8 | 9.9 | 8.8 | 7.6 | 3.2 | 3.2 | 64 | NA | -2.1 | False,False;False,False;False,False | [False, False, False] | ['2025-08-14', 164.0, '2026-03-30', 36.3] | 78.14 | Dec 2025:06/02/2026,Sep 2025:14/11/2025,Jun 2025:13/08/2025 | Brooks Laboratories Limited | 17.5 | 35.3 | Jun 2025:NA | 18 | 43.3 | 54.5 | 54.5 | 5.5 | 7.98 | 9.58 | -1.46 | -2.13 | -3.96 | -2.41 | -9.61 | -31.1 | 358.2 | 1.87 | 2.71 | 3.25 | -0.5 | -0.81 | -1.51 | -0.92 | -3.66 | -31 | 330.9 | -3.38 | -7.46 | 16.57 | 23.45 | 25.51 | 23.32 | 20.52 | 20.79 | 17.93 | 17.72 | -29.3 | -19.2 | NA | 4.41 | 10.75 | 12.27 | -5.4 | -7.31 | -16.4 | -10.71 | -53.78 | -59 | 160.3 | Dec 2025 | -12.21 | -9.93 | 0.07 | 5.76 | 9.8 | 0.08 | 0 | 0 | 2.52 | 9.57 | 20.8 | Brooks Laboratories Limited manufactures and sells pharmaceuticals in India and internationally. The company offers liquid and dry powder injection, carbapenem dry powder injectables, tablets, oral suspension, dry syrup, and eye/ear drops. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India. **Website:** [https://www.brookslabs.net](https://www.brookslabs.net) | 52.62 | 36.91 | 0.09 | 10.38 | 52.62 | 0.01 | 10.38 | 1.82 | 218.32 | 8.97 | 2.46 | ||||||
| 60 | 10 | 51 | 29 | 06/10/2023 | Pharmaceuticals | 313 | -3.7 | 0.9 | 3.5 | -14.1 | -34.7 | -38.3 | 53.6 | 16.6 | DAILY | 57.71 | 77.62 | 70.35 | 57.68 | 55.63 | 74.58 | 58.61 | 56.72 | 56.71 | 57.22 | 0.7 | False | False | 1.36 | NA | False | False | False | 120 | Healthcare | 25.1 | False | False | False | False | True | 20/03/2026 | True | 6 | False | 20 | 0.48 | 1.7 | 1.2 | 1.3 | False | 118489.7 | 86732.54 | 95166.84 | 93908.21 | 95985.43 | False | 57.9 | 11.47 | 12.56 | 12.19 | 47.4 | 4.6 | 7.3 | 6.9 | 6.7 | 6.4 | 6.4 | 73.2 | NA | 0.6 | False,False;False,False;False,False | [False, False, False] | ['2025-06-12', 124.4, '2026-03-04', 49.5] | 65.89 | Dec 2025:11/02/2026,Sep 2025:11/11/2025,Jun 2025:08/08/2025 | Valiant Laboratories Limited | -12.4 | 3.9 | Jun 2025:NA | 7 | 10.1 | 16.3 | 21.5 | -7.06 | 0.2 | 1.82 | 0.7 | 2.35 | -4.74 | -0.51 | -1.24 | -3630 | -400.4 | -1.3 | 0.04 | 0.34 | 0.13 | 0.43 | -0.87 | -0.09 | -0.23 | -3350 | -402.3 | -0.41 | 0.06 | 52.46 | 46.2 | 46.82 | 57.79 | 35.23 | 21.48 | 18.88 | 30.59 | 13.5 | 48.9 | NA | -1.7 | 0.17 | 5.1 | 6.61 | 1.76 | -31.38 | -12.66 | -14.81 | -1100 | -196.6 | Dec 2025 | -1.43 | -0.95 | 0.17 | 2.66 | -72.1 | -0.01 | 0 | 0 | NA | -11.1 | 64.58 | Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP. **Website:** [https://valiantlabs.in](https://valiantlabs.in) | 74.94 | 25.05 | 0.01 | 0 | 74.94 | 0.02 | 0 | 0.99 | 349.85 | 66.64 | 1.72 | |||||||
| 61 | 5 | 43 | 8 | 01/01/1996 | Pharmaceuticals | 207 | -0.9 | 4.9 | 2 | -25.4 | -38.2 | -43.8 | 54.8 | 32 | DAILY | 58.23 | 86.52 | 79.04 | 61.7 | 53.28 | 82.85 | 60.88 | 55.36 | 55.22 | 54.96 | 0.7 | False | False | 1.49 | NA | False | False | False | 174.9 | Healthcare | 41.8 | False | False | False | False | True | 23/03/2026 | False | 5.2 | False | 20 | 0.19 | 1.5 | 0.9 | 0.6 | True | 125941.7 | 70001 | 61257.2 | 81798.74 | 103740.17 | False | 64 | 5.54 | 5.24 | 5.43 | 37.5 | 8.3 | 8.6 | 7.7 | 6.5 | 0.8 | 0.8 | 78.2 | NA | 0.9 | False,False;False,False;False,False | [False, False, False] | ['2025-05-29', 128.8, '2026-03-30', 44.1] | 73.36 | Dec 2025:29/01/2026,Sep 2025:12/11/2025,Jun 2025:01/08/2025 | Lyka Labs Limited | -20.6 | 2.3 | Jun 2025:NA | 11.8 | 20.4 | 28.9 | 28.9 | -0.15 | -3.22 | 0.99 | 2.03 | 2.7 | 1.91 | 1.29 | -2.09 | 95.3 | -105.6 | 0 | -0.94 | 0.26 | 0.5 | 0.76 | 0.59 | 0.4 | -0.63 | 100 | -100 | 2.24 | -0.75 | 30.73 | 36.66 | 33.03 | 33.43 | 33.8 | 41.16 | 30.11 | 27.77 | -16.2 | -9.1 | 17.63 | 5.37 | -6.93 | 11.14 | 12.2 | 15.36 | 12.03 | 12.32 | 7.27 | 177.5 | -65 | Dec 2025 | 9.31 | 9.91 | 0.31 | 5.13 | -323.5 | 0 | 0 | 0 | NA | NA | 45.74 | Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India. **Website:** [https://www.lykalabs.com](https://www.lykalabs.com) | 58.16 | 40.99 | 0.17 | 0.66 | 58.16 | 0.17 | 0.66 | 2.06 | 238.47 | 22.56 | 1.78 | |||||||
| 62 | 4 | 95 | 43 | 02/12/2015 | Pharmaceuticals | 126 | -4 | 8.7 | 22.9 | -9.7 | -46.3 | -65.6 | 66.9 | 51.1 | DAILY | 22.96 | 35.88 | 31.7 | 20.69 | 19.24 | 35.52 | 21.43 | 20.06 | 20.07 | 20.9 | 0.4 | False | False | 1.88 | NA | False | False | False | 85.7 | Healthcare | 34 | False | False | False | False | False | False | 3.3 | False | 10 | 0.91 | 1.5 | 1.2 | 1.2 | True | 209866.8 | 166781.86 | 179218.77 | 183495.37 | 208224.22 | False | 37.5 | 1.44 | 2.37 | 3.08 | 0 | 8.2 | 7.4 | 7.7 | 7.1 | 3.2 | 3.2 | 89.4 | NA | -0.9 | False,False;False,False;False,False | [False, False, False] | ['2025-04-11', 69.4, '2026-03-27', 15.2] | 25.5 | Dec 2025:28/01/2026,Sep 2025:11/11/2025,Jun 2025:05/08/2025 | BALAXI PHARMACEUTICALS LIMITED | -8.7 | 2.9 | Jun 2025:https://nsearchives.nseindia.com/corporate/BALAXI_08082025172343_08082025.pdf,Sep 2025:https://nsearchives.nseindia.com/corporate/BALAXI_14112025151312_INVESTOR_PRESENTATION.pdf,Dec 2025:https://nsearchives.nseindia.com/corporate/BALAXI_29012026144532_PRESENTATION_Q3.pdf | 10.7 | 26.1 | 36.4 | 37.7 | 0.31 | 0.21 | 0.29 | 8.64 | 5.36 | 4.59 | 6.48 | 10.93 | 47.6 | -94.2 | 0.06 | 0.04 | 0.05 | 1.57 | 0.97 | 0.83 | 1.17 | 2.01 | 50 | -93.8 | 4.54 | -0.44 | 72.54 | 56.18 | 70.74 | 76.27 | 73.29 | 77.38 | 65.62 | 59.83 | 29.1 | -1 | 45.01 | 4.26 | 2.06 | 5.88 | 16.45 | 5.44 | 13.69 | 15.38 | 22.51 | 106.8 | -21.7 | Dec 2025 | 11.61 | 12.95 | 0.24 | 7.6 | 13.4 | -1.76 | 0 | 0 | -0.7 | 95.67 | 12.51 | Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. Balaxi Pharmaceuticals Limited was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited. **Website:** [https://balaxipharma.in](https://balaxipharma.in) | 65.99 | 32.24 | 1.74 | 0.02 | 65.99 | 3.5 | 0.02 | 0.53 | 144.43 | 7.53 | 0.52 | ||||||||
| 63 | 4 | 23 | 4 | 21/09/2017 | Pharmaceuticals | 37 | 4.9 | 21.2 | -2.3 | -30.8 | -32.3 | -57.7 | 60.2 | 33.3 | DAILY | 7.56 | 9.85 | 9.62 | 7.89 | 6.95 | 10.82 | 7.75 | 7.02 | 7 | 6.84 | 0 | False | False | 2.32 | NA | False | False | False | 41.2 | Healthcare | 46.4 | False | False | False | False | True | 27/03/2026 | False | 5.8 | False | 5 | 1.29 | 0.3 | 0.2 | 0.3 | False | 53147.35 | 47960.46 | 82737.46 | 54546.89 | 52055.54 | False | 49.2 | 4.81 | 6.52 | 6.41 | 69.2 | 4.1 | 6.5 | 6.6 | 6.5 | 12.8 | 12.8 | 96.5 | NA | 0 | False,False;False,False;False,False | [True, False, False] | ['2025-05-22', 19.0, '2026-03-30', 5.7] | 8.93 | Dec 2025:13/02/2026,Sep 2025:14/11/2025,Jun 2025:13/08/2025 | Lasa Supergenerics Limited | -15.3 | 2.5 | Jun 2025:NA | 14.1 | 21.4 | 25.1 | 31.7 | -2.55 | -6.25 | -21.12 | -14.29 | 5.49 | -3.23 | -2.73 | -15.3 | 59.2 | -146.4 | -0.51 | -1.25 | -4.22 | -2.85 | 1.1 | -0.64 | -0.54 | -3.05 | 59.2 | -146.4 | -2.95 | -4.34 | 2.2 | 3.06 | 20.01 | 39.14 | 33.08 | 39.39 | 30.84 | 22.82 | -28.1 | -93.3 | -3.16 | -34.09 | -130.72 | -2.5 | 8.71 | 0.82 | 2.01 | 5.84 | -17.48 | 73.9 | -4257.3 | Dec 2025 | 1.01 | -1 | 0.13 | -2.86 | -0.9 | 0 | 0 | 0 | -4.97 | -3.71 | 30.9 | Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India. **Website:** [https://lasalabs.com](https://lasalabs.com) | 53.65 | 46.34 | 0 | 0 | 53.65 | 0 | 0 | 0.67 | 44.46 | 62.62 | 0.69 | |||||||
| 64 | 3 | 1 | 1 | 27/10/2021 | Pharmaceuticals | 321 | -1.5 | 3.5 | -17.3 | -39.3 | -22.9 | -52.2 | 53.4 | 9.2 | DAILY | 236.95 | 352.85 | 342.22 | 298.75 | 251.82 | 354.17 | 288.45 | 253.47 | 252.01 | 238.09 | 1.3 | False | False | 0.81 | NA | False | False | False | 112 | Healthcare | 59.5 | False | False | False | False | False | False | 3.5 | False | 20 | 0.23 | 2.9 | 1.9 | 2.1 | True | 51091.65 | 33030.46 | 36250.7 | 40360.73 | 49283.29 | False | 34.7 | 7.67 | 5.09 | 4.16 | 78.6 | 4.9 | 5.8 | 5.4 | 5.2 | 40 | 40 | 80.7 | NA | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-04-11', 508.0, '2026-03-30', 216.9] | 353.3 | Dec 2025:13/02/2026,Sep 2025:14/11/2025,Jun 2025:12/08/2025 | Medicamen Biotech Limited | -32.9 | 1.9 | Jun 2025:NA | 9.3 | 9.3 | 13.2 | 26.8 | ['DAILY', '2026-04-09', '2026-04-08']['WEEKLY', '2026-04-06', '2026-03-30'] | 2.59 | 2.21 | 1.64 | 2.4 | 2.52 | 0.91 | 0.8 | 2.04 | 17.2 | 2.8 | 1.91 | 1.63 | 1.59 | 1.89 | 1.98 | 1.15 | 1.06 | 1.68 | 17.2 | -3.5 | 7.43 | 10.46 | 43.49 | 42.23 | 38.45 | 26 | 41.14 | 44.74 | 43.05 | 47.32 | 3 | 5.7 | 5.24 | 11.68 | 11.96 | 10.48 | -4.23 | 15.17 | 11.87 | 8.01 | 12.15 | -2.3 | -23 | Dec 2025 | 4.43 | 6.77 | 0.11 | 8.7 | 35.7 | -0.03 | -0.15 | 0 | -2.58 | 31.01 | 53.98 | Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarial, vitamins and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India. **Website:** [https://www.medicamen.com](https://www.medicamen.com) | 40.46 | 59.02 | 0.02 | 0.44 | 40.46 | 0.05 | 0.59 | 1.18 | 308.91 | 15.72 | 2.06 | |||||||
| 65 | 3 | 13 | 1 | 18/07/2005 | Pharmaceuticals | 207 | -0.9 | 6.5 | -5.3 | -41.1 | -24.2 | -52.8 | 62.2 | 14.9 | DAILY | 10.69 | 15.6 | 14.87 | 12.04 | 10.6 | 16.57 | 12.13 | 10.74 | 10.69 | 10.35 | 0.6 | False | False | 9.36 | NA | False | False | False | 24.4 | Healthcare | 48.2 | False | False | False | False | False | False | 4.3 | False | 10 | 0.93 | 1.5 | 1.1 | 5 | False | 522167.75 | 363283.04 | 1315027.7 | 620650.13 | 503091.73 | False | 49.7 | 3.47 | 3.03 | 1.99 | 66.7 | 4.6 | 4.5 | 4.5 | 4.3 | 28.8 | 28.8 | 82.4 | NA | 1.3 | False,False;False,False;False,False | [True, False, False] | ['2025-05-28', 28.2, '2026-03-30', 9.3] | 14.62 | Dec 2025:23/01/2026,Sep 2025:14/11/2025,Jun 2025:14/08/2025 | Nectar Lifesciences Limited | -26.9 | 3.6 | Jun 2025:NA | 9.8 | 12.1 | 15.8 | 21.8 | 14.27 | -176.01 | -63.23 | -130.09 | 7.84 | 5.6 | 2.97 | 0.59 | 108.1 | 82 | 0.64 | -7.85 | -2.82 | -5.8 | 0.35 | 0.25 | 0.13 | 0.03 | 108.2 | 82.9 | -5.07 | 0.22 | 0 | 0.71 | 5.24 | 430.7 | 0.01 | 5.74 | 359.3 | 441.38 | -100 | -100 | -6.77 | NA | 77.46 | -16.03 | -35.83 | -500 | -10.28 | 11.08 | 10.99 | NA | NA | Dec 2025 | -11.23 | -5.36 | 0.64 | -35.85 | -0.7 | -0.04 | -0.08 | 6.94 | NA | 4.18 | 142.48 | Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company's active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India. **Website:** [https://www.neclife.com](https://www.neclife.com) | 51.84 | 44.02 | 0.58 | 0 | 44.9 | 0.62 | 0.08 | 0.33 | 660 | -4.25 | 1.51 | ||||||||
| 66 | 3 | 26 | 7 | 01/11/2023 | Pharmaceuticals | 6416 | -1.2 | 3.5 | -1.5 | -26 | -43.4 | -40.9 | 64 | 13.8 | DAILY | 369.9 | 604.66 | 527.26 | 384.15 | 359.47 | 537.45 | 394.42 | 364.3 | 363.64 | 360.51 | 22.2 | False | False | 3.5 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 159 | Healthcare | 20.2 | False | False | False | False | False | False | 4.8 | False | 10 | 0.6 | 35.1 | 47.5 | 32.6 | False | 621348.75 | 825479.3 | 658789.1 | 711228.56 | 641752 | False | 36.1 | 11.45 | 2.73 | 2.17 | 94 | 4.8 | 5.6 | 5.2 | 5.2 | 0 | 0 | 64 | NA | -0.7 | False,False;False,False;False,False | [False, False, False] | ['2025-07-21', 1027.8, '2026-03-30', 325.0] | 409.4 | Dec 2025:13/02/2026,Sep 2025:04/11/2025,Jun 2025:22/07/2025 | Blue Jet Healthcare Limited | -6.9 | 11.6 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fd75abe1-87b3-4d37-9bf5-2d7e90864f2e.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ac2c4f8-d539-49bf-a366-262dcf1f43eb.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/bb8db615-1ee1-4364-b96b-062c4cff8cd5.pdf | 7 | 12.2 | 14.9 | 16.2 | 40.17 | 52.14 | 91.17 | 110.1 | 98.98 | 58.35 | 37.78 | 39.65 | -23 | -59.4 | 2.32 | 3.01 | 5.26 | 6.35 | 5.71 | 3.36 | 2.18 | 2.29 | -22.9 | -59.4 | 17.59 | 9.44 | 192.41 | 165.48 | 354.76 | 340.45 | 318.38 | 208.26 | 162.9 | 183.95 | 16.3 | -39.6 | 13.86 | 24.37 | 33.21 | 34.11 | 41.11 | 38.95 | 33.37 | 27.17 | 28.85 | -26.6 | -37.4 | Dec 2025 | 30.24 | 39.75 | 0.02 | 34.45 | 21.9 | -0.69 | 1.02 | 0 | 1.21 | 39.86 | 41.8 | Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, Spain, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India. **Website:** [https://www.bluejethealthcare.com](https://www.bluejethealthcare.com) | 79.81 | 14.41 | 1.14 | 4.65 | 79.81 | 1.83 | 3.63 | 5.11 | 6237.04 | 14.82 | 5.92 | ||||||||
| 67 | 2 | 12 | 22 | 23/05/2005 | Pharmaceuticals | 50 | 1.3 | 8.2 | -5.6 | -17.3 | -53.9 | -57.2 | 66.3 | 40.2 | DAILY | 31.97 | 55.59 | 46.2 | 32.18 | 30.33 | 51.35 | 32.38 | 30.46 | 30.42 | 30.31 | 0.1 | False | False | 1.02 | NA | False | False | False | 72.4 | Healthcare | 64.3 | False | False | False | False | False | False | 7.3 | False | 2 | 0.95 | 0.5 | 1 | 2 | False | 41570.2 | 89261.98 | 105053.84 | 83607.74 | 45649.03 | False | 18 | 4.97 | 11.51 | 13.68 | 93.3 | 6.3 | 6 | 6 | 5.9 | 8.8 | 8.8 | 92.8 | NA | 0.3 | False,False;False,False;False,False | [True, False, False] | ['2025-07-22', 95.0, '2025-12-29', 22.8] | 51.81 | Dec 2025:15/01/2026,Sep 2025:20/11/2025,Jun 2025:07/08/2025 | Mangalam Drugs And Organics Limited | -28.6 | 21.5 | Jun 2025:NA | 11.8 | 16.8 | 19.8 | 25.1 | -9.78 | -7.25 | -13.73 | 0.15 | 1.4 | 2.69 | 2.68 | 3.53 | -34.9 | -798.6 | -6.18 | -4.58 | -8.67 | 0.09 | 0.88 | 1.7 | 1.69 | 2.23 | -34.9 | -802.3 | 4.37 | -5.72 | 58.49 | 49.54 | 57.35 | 73.04 | 88.71 | 79.94 | 76.53 | 102.24 | 18.1 | -34.1 | 2.42 | -2.51 | -5.71 | -7.86 | 13.91 | 9.89 | 10.87 | 10.7 | 11.43 | 56 | -125.4 | Dec 2025 | 4.71 | 8.03 | 0.74 | 0.57 | -1.7 | 0.02 | 0 | -14.65 | NA | -1.29 | 12.62 | Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers API products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; and ortho phenoxy methane sulfonanilide, tenofovir alafenamide base, and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol; bictegravir Na, aripiprazole, risperidone, olanzapine, and etodolac; and develops tafenoquine succinate and pretomanid. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. The company was incorporated in 1972 and is based in Mumbai, India. **Website:** [https://www.mangalamdrugs.com](https://www.mangalamdrugs.com) | 35.65 | 64.22 | 0.13 | 0 | 50.3 | 0.11 | 0 | 0.4 | 141.58 | 83.28 | 0.59 | ||||||||
| 68 | 0 | 83 | 3 | 09/03/2020 | Pharmaceuticals | 12121 | 2.4 | 3.1 | 12.1 | -33.4 | -64.1 | -72.1 | 72.5 | 18.8 | DAILY | 316.85 | 673.45 | 571.82 | 320.43 | 301.35 | 608.3 | 340.97 | 306.38 | 306 | 306.27 | 24.7 | True | False | 16.26 | Nifty MNC,Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | NA | Healthcare | 42.5 | False | False | False | False | False | False | 5.8 | False | 20 | 1.69 | 56 | 83.1 | 75.9 | False | 821429.85 | 1140665.2 | 889958.69 | 1010461.49 | 921543.58 | False | 2.9 | 0.13 | 0 | 0 | 100 | 4.3 | 3.9 | 4.3 | 4.4 | 0 | 0 | 72.5 | NA | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-05-02', 1152.3, '2026-03-09', 266.7] | 350.75 | Dec 2025:12/02/2026,Sep 2025:12/11/2025,Jun 2025:13/08/2025 | Suven Pharmaceuticals Limited | -9.7 | 1.2 | Jun 2025:https://www.bseindia.com/xml-data/corpfiling/AttachHis/536f1fc9-8042-4b24-9b24-c52e2c8af247.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c6d703a0-9c33-483f-aad5-2a83e1acbde8.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/58387b0d-b3f2-43fd-9542-6c89585316cd.pdf | 8.7 | 10 | 10 | 14 | [320.9, '23/02/2026', 'DAILY'] | 29.02 | 66.39 | 46.4 | 117.15 | 153.48 | 138.24 | 75.37 | 53.37 | -56.3 | -81.1 | 0.96 | 1.94 | 1.28 | 4.73 | 6.01 | 5.44 | 2.96 | 2.1 | -50.5 | -84 | 10.52 | 11.8 | 544.55 | 555.57 | 549.31 | 840.42 | 676.23 | 603.77 | 488.08 | 252.93 | -2 | -19.5 | 7.51 | 17.51 | 21.77 | 20.39 | 27.27 | 35.1 | 34.01 | 25.63 | 29 | -19.6 | -50.1 | Dec 2025 | 12.67 | 14.89 | 0.12 | 22.39 | 35.6 | -0.5 | 0.76 | 0 | -2.49 | 82.51 | 35.39 | Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is based in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited. **Website:** [https://www.cohance.com](https://www.cohance.com) | 57.49 | 14.91 | 6.01 | 21.57 | 57.49 | 6.51 | 20.81 | 3.2 | 12480.91 | 20.61 | 5.01 |
Quarter | EPS | QoQ EPS | YoY EPS | Sales(Cr.) | QoQ Sales | YoY Sales | OPM |
|---|---|---|---|---|---|---|---|
Dec 25 | 4.52 | 3.9 | 1121.6 | 162 | 1.5 | 21.7 | 16.42 |
Sep 25 | 4.35 | 6.1 | 77.6 | 160 | -1.9 | -0.7 | 16.11 |
Jun 25 | 4.1 | -33.7 | 1181.3 | 163 | -5.1 | 24.5 | 14.98 |
Mar 25 | 6.18 | 1570.3 | -39.8 | 172 | 28.9 | 23.4 | 17.23 |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Website: https://www.wanbury.com
Wanbury Limited is an established pharmaceutical company with over three decades of operational history, focused on the manufacturing of Active Pharmaceutical Ingredients (APIs) and branded formulations. The company has undergone a significant operational and financial turnaround, transforming from a period of debt restructuring to a phase of structured growth and profitability. This transformation was marked by a strategic deleveraging of the balance sheet, including a ~75% reduction from peak debt and a substantial refinancing of high-cost debt, which has improved financial stability and positioned the company for future expansion.
The business is structured into two primary verticals. The API segment is the cornerstone of the company, contributing 88% of the total revenue. It is heavily export-oriented, with over 80% of its sales directed towards developed and regulated markets such as the USA, Europe, and Brazil. Wanbury has established itself as a global market leader in several key molecules, most notably Metformin (anti-diabetic) and Sertraline (anti-depressant). The company operates two USFDA-approved API manufacturing facilities in Tanuku, Andhra Pradesh, and Patalganga, Maharashtra.
The second vertical is the domestic Formulations business, which contributes the remaining 12% of revenue. This business, which began with the acquisition of Wander Ltd. from Sandoz in 1995, is currently in a rebuilding phase. It focuses on acute and semi-chronic therapeutic areas like anti-cold & cough, anti-infectives, and supplements, operating on an asset-light, outsourced manufacturing model. The strategy is to leverage its legacy brand equity to achieve profitability and transition towards more specialized and chronic therapeutic segments. The company is managed by an experienced board with deep expertise in the pharmaceutical, finance, and technology sectors.
Official Website: http://www.wanbury.com/
The company has executed a successful financial turnaround, evidenced by strong revenue growth, exponential profit expansion, significant debt reduction, and vastly improved return ratios.
Wanbury's uniqueness stems from its dominant global market share in core APIs, a strong regulatory compliance record in developed markets, and a balanced dual-business model.
Growth is strategically planned, relying on a robust pipeline of new API products for regulated markets and a well-defined turnaround and expansion strategy for the domestic formulations business.
The company has clear opportunities to enhance value by diversifying its API portfolio into more complex molecules and by executing a strategic pivot of its formulations business towards higher-growth segments.
Wanbury is undertaking a significant, well-funded capex cycle of over ₹120 Cr projected for FY26-FY27, primarily focused on brownfield expansion to facilitate new product launches and enhance existing capacity.
The company's future plans are centered on a disciplined expansion of its API portfolio into higher-value products and a strategic pivot of its formulations business towards sustainable profitability and chronic therapies.
Profitability margins have expanded significantly due to operational efficiencies and a favorable product mix, with clear levers in place for continued improvement going forward.
Although direct competitors are not detailed, the company's significant global market share in its core products and strong regulatory standing demonstrate a robust and defensible competitive position.
The primary risks facing the company are its high product concentration in the API segment, the continuous need for stringent regulatory compliance, and the execution risk associated with its ambitious growth plans.
Recent developments underscore positive momentum, including key international regulatory clearances, the successful commercial launch of a new high-value API product, and a significant reduction in financing costs.
Disclaimer: This stock summary is generated by AI. ChartsMaze does not guarantee its accuracy, completeness, or timeliness. The data may be outdated and may not reflect real-time events or news. Please verify the information independently before making any investment decisions. For more details, check our Terms & Conditions.